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Abstract 
The increasing numbers of critically ill obese patients in the intensive care unit (ICU) and 
the high frequency of antimicrobial prescription in these patients present a challenge for 
prescribing effective antimicrobial doses. Critically ill obese patients have greater infection-
related morbidity and mortality than their non-obese counterparts. The underlying 
explanation for these inferior outcomes remains unclear, although sub-optimal 
antimicrobial dosing may be a contributing factor. Unfortunately there is a paucity of 
research and no recognised guidelines to assist clinicians with dosing antimicrobials in 
these patients who commonly develop dramatic physiological changes that can lead to 
significantly altered drug concentrations, and therefore, sub-optimal treatment.  
Critical illness pathologies, such as sepsis and septic shock are reported to alter the 
pharmacokinetics of many antimicrobials, including piperacillin, meropenem and 
fluconazole. Along with the alterations in the pharmacokinetics of these agents caused by 
obesity, sub-therapeutic concentrations of these drugs are likely in critically ill obese 
patients.  
This Thesis addresses the limitations of current knowledge by describing the plasma 
pharmacokinetics of piperacillin, meropenem and fluconazole in critically ill non-obese, 
obese and morbidly obese patients. The Thesis then provides dosing recommendations 
which can be used for more effective antibiotic dosing. 
Firstly a structured review of the effect of obesity on the pharmacokinetics of antimicrobials 
in critically ill patients was performed. The review concluded that the presence of obesity 
augments the pharmacokinetic changes of antimicrobials in critical illness. Furthermore, 
this chapter also provides suggested dosing regimens for use in critically ill obese patients 
based on the published literature.  
To investigate the effect of obesity on antimicrobial trough concentrations and 
achievement of target exposures in obese and non-obese critically ill patients, a large 
retrospective study (n = 1400) of therapeutic drug monitoring data of piperacillin and 
meropenem was performed. This study found that piperacillin concentrations were 
significantly affected by the presence of obesity, with no significant differences evident for 
meropenem.  
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To further explore the effect of obesity using a more descriptive approach, prospective 
pharmacokinetic studies were conducted with piperacillin/ tazobactam (n=37), meropenem 
(n=19) and fluconazole (n=21) in critically ill patients across different body mass index 
(BMI) classifications including non-obese (BMI 18.5 - 29.9 kg/m2), obese (BMI 30 - 39.9 
kg/m2), and morbidly-obese (BMI ≥ 40 kg/m2). The included patients had widely varying 
BMIs, but typical age and sex distributions as encountered in ICUs. Using a population 
pharmacokinetic modelling approach, it was concluded that BMI only had a small effect on 
antimicrobial volume of distribution, whilst measured creatinine clearance had a significant 
effect on drug clearance. Using Monte Carlo dosing simulations, it was concluded that 
dose adjustment based on renal function (i.e. measured creatinine clearance) was the 
most important factor to be considered by clinicians for effective dosing in both obese and 
non-obese critically ill patients. For fluconazole, weight-based dosing was found to be 
most appropriate for achieving therapeutic drug exposures. 
The overall results of this Thesis suggest that the BMI does not have a profound effect on 
antimicrobial dosing requirements for critically ill obese patients. Renal function, which was 
best described by creatinine clearance, was the major determinant of dosing requirements 
in individual patients. It can be concluded that although a higher than standard dose may 
be appropriate for the first 24-h of treatment, on subsequent days, dosing need only be 
based on robust estimates of renal function. 
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                            based on total body weight 
CI Continuous infusion 
CIs Confidence intervals 
CL Clearance 
CLCR Creatinine clearance 
cm Centimetre 
CMAX Peak concentration 
CMAX/MIC The ratio of the peak concentration to the minimal inhibitory  
                           concentration 
CRRT Continuous renal replacement therapy 
CVVHDF Continuous veno-venous haemodiafiltration 
CYP2E1 Cytochrome P450 2E1 
CYP3A4 Cytochrome P450 3A4 
  
XXI 
DALI Defining Antibiotic Levels in Intensive care unit 
DWCF Dosing weight correction factor 
ECCMID European Congress of Clinical Microbiology and Infectious Diseases 
EUCAST European Committee for Antimicrobial Susceptibility 
fAUC0-24/MIC The ratio of free antimicrobial area under concentration curve 
                            from 0-24 h to the minimal inhibitory concentration 
FFM Free fat mass 
fT>MIC The time that the free concentration of the antimicrobial remains  
                           above the minimal inhibitory concentration 
FTA Fraction of target attainment 
Fe Female 
g                         Gram 
GFR Glomerular filtration rate 
h Hour 
HPLC-UV High performance liquid chromatography with ultraviolet detection 
HREC Human Research Ethics Committee 
Ht Height 
IBM-SPSS Statistical software package 
IBW Ideal body weight 
ICU Intensive care unite 
II Intermittent 
IQR Interquartile ranges 
i.v. Intravenous  
KCP Rate constant for antimicrobial distribution from the central to  
                           peripheral compartment 
KPC Rate constant for antimicrobial distribution from the peripheral to  
                           central compartment 
Kg Kilogram 
L Litre 
LBW Lean body weight 
LLOQ                  Lower limit of quantification   
M Male 
m-ob Morbidly obese 
m2 Metre square 
  
XXII 
MD Maryland 
MDRD Modification of Diet in Renal Disease 
MIC Minimum inhibitory concentration 
min Minute(s) 
mL Millilitre 
n number 
n-ob Non-obese 
NIH National Institute of Health 
O Scaling factor of obesity 
ob Obese 
OR Odd ratio 
PD pharmacodynamics 
PK Pharmacokinetics 
PK/PD Pharmacokinetics / pharmacodynamics 
p.o Oral route 
PTA Probability of target attainment 
RRT Renal replacement therapy 
SD Standard deviation 
SOFA Sequential Organ Failure Assessment 
spp.                     Species  
TBW Total body weight 
TDM Therapeutic drug monitoring 
TVCL The typical value of antimicrobial clearance 
TVVc The typical value of volume of distribution in the central  
                           compartment 
USA/US United States of America / United States 
UV                       Ultra-violet  
VPC Visual prediction check 
Vc Volume of distribution for central compartment 
Vd Volume of distribution 
Vp Volume of distribution for peripheral compartment 
Vs.  Versus 
Vss Volume of distribution at steady state 
WHO World Health Organisation
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1.1 An overview  
1.1.1 Critical illness 
Critical illness is defined as a medical condition where continuous monitoring is required 
due to the severity of disease. Critically ill patients may experience physiological instability, 
including dysfunction of vital organs, requiring intensive treatment. These treatments are 
often substantially different to those provided to non-critically ill patients. Indeed, drug 
therapy is a central tool for intensive care staff to reverse underlying disease processes. 
However, the pathophysiological changes that occur during critical illness as well as the 
associated medical interventions can have significant effects on the pharmacokinetics (PK) 
of many drugs. An understanding of the individual patient’s pathophysiology is crucial for 
optimization of drug therapy to improve patient outcomes.  
In the context of antimicrobials, effective therapy is highly important in critically ill patients 
given the high morbidity and mortality associated with severe infections in this group. 
However, the effect of the pathophysiological alterations in critical illness on antimicrobial 
PK may be profound thereby providing major challenges for clinicians aiming to optimise 
drug dosing. Indeed, optimised initial antimicrobial therapy is a central goal of therapy 
because it is associated with significantly improved patient outcomes. An individualized 
approach to therapy where antimicrobial doses are adapted to the clinical context of the 
patient can enable the rapid achievement of targeted antimicrobial concentrations which 
can maximize the likelihood of clinical and bacteriological success.  
1.1.2 Obesity 
Like critical illness, obesity is a major challenge for the health system. Obesity is a 
condition characterised by increased body fat, and has been shown to negatively influence 
an individual’s health. The degree of obesity is classified according to body mass index 
(BMI). Individuals can be considered as normal weight, overweight, obese or morbidly 
obese. The BMI is a metric measurement obtained by dividing individual’s weight (kg) by 
the square of height (m2). Organisations, such as the World Health Organisation (WHO) 
and National Institute of Health (NIH), USA have endorsed BMI as the preferred 
classification of obesity as the following classes; underweight (BMI ≤ 18.5 kg/m2), normal 
weight (18.5 – 29.9 kg/m2), obese (BMI 30- 39.9 kg/m2) and morbidly obese (BMI ≥ 40 
kg/m2).     
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Obesity is a growing health concern and is associated with increased morbidity and 
mortality.1,2 It is a risk factor for developing cardiovascular disease, pulmonary disease 
and diabetes amongst other diseases.3 It has also been found to promote other 
physiological changes in obese individuals including changes in regional blood flow, 
increases in oedema as well as adipose and lean body mass. Increases in size of organs, 
including the kidney has also been described.4 Furthermore, obesity is a significant risk 
factor for community and hospital acquired infections that may result in critical illness and 
intensive care unit (ICU) admission.5-7        
The combination of obesity and critical illness is likely to bring exacerbate changes in the 
PK of antimicrobials. Treating critically ill obese patients is considered extremely 
challenging as these patients invariably have unstable organ function. To date, there are 
no clear guidelines or protocols for drug dosing in this population meaning that clinicians 
have little guidance to ensure optimised antimicrobial dosing regimens are used in these 
patients.  
1.1.3 Pharmacokinetics and pharmacodynamics 
PK describes the relationship between dose and the concentration-time course of a drug in 
the body. After drug administration, different kinetic processes can occur, where the drug 
is absorbed into the blood, distributed to the body tissues and later eliminated by 
metabolism or excretion.8 Pharmacodynamics (PD) describes the relationship of the drug 
concentrations and therapeutic effect.8 Together, PK and PD (PK/PD) describe the 
relationship of the entire process from drug administration, to clinical response.  
In critically ill obese patients, there are significant concerns that standard antimicrobial 
dosing regimens may not be sufficient to achieve adequate drug concentrations.  
Therefore, inappropriate antimicrobial dosing is likely to be more common in these 
patients, which can lead to insufficient drug concentrations and possible therapeutic 
failure. To ensure that these patients achieve target drug exposures, dose individualization 
is essential and should be based on patient’s organ function. However, to determine which 
doses should be used in critically ill obese patients, research that describes the PK of 
these drugs is required. 
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This Thesis investigated three of most commonly prescribed antimicrobials in the ICU, 
meropenem, piperacillin and fluconazole. Meropenem and piperacillin are extended 
spectrum β-lactam antibiotics frequently prescribed for ICU-acquired infections as 
empirical or directed therapy. These two agents show time-dependent activity, where the 
bacterial killing is related to the time the unbound antibiotic concentrations are maintained 
above the minimum inhibitory concentration (MIC) of the infecting pathogen (fT>MIC). 
Fluconazole is a triazole antifungal derivative that is commonly used in the ICU to treat 
infections caused by fungal pathogens, such as Candida species. It exhibits concentration- 
and time-dependent antifungal activity.9 The PK/PD index of fluconazole which is 
associated with maximal fungal killing, is described as the ratio of free drug area under the 
concentration-time curve from 0 to 24 h to MIC (fAUC0-24/MIC).9  
Chapter two of this Thesis is a structured review that provides further background to this 
clinical and research area. Chapter two reviews the potential PK changes of antimicrobials 
in critically ill obese patients and the implication for appropriate dosing.  
Chapter three is a retrospective study that aims to determine the effect of obesity on 
unbound trough concentrations and the achievement of PK/PD targets of piperacillin and 
meropenem in critically ill patients.  
Chapters four, five and six are prospective studies, which describe the population PK of 
meropenem, piperacillin and fluconazole, respectively, in cohorts of critically ill patients 
including obese and morbidly obese patients.  
Chapter seven includes a general discussion on the findings of this Thesis and provides 
suggestions for further research.   
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1.2 Aims 
The overall aim of this Thesis was to investigate the effect of obesity on the PK of 
commonly used antimicrobials in the ICU, meropenem, piperacillin and fluconazole. The 
specific aims of this Thesis were to:  
1. Critically review published literature to describe the effect of obesity on the PK of 
antimicrobials in critically ill patients 
2. Compare critically ill obese and non-obese patients for piperacillin and meropenem 
trough concentrations, as well as achievement of PK/PD targets 
3. Describe the population PK of meropenem in a cohort of critically ill patients 
including obese and morbidly obese patients 
4. Describe the population PK of piperacillin in a cohort of critically ill patients including 
obese and morbidly obese patients 
5. Describe the population PK of fluconazole in a cohort of critically ill patients 
including obese and morbidly obese patients. 
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Chapter 2. The effect of obesity on the pharmacokinetics of antimicrobials in 
critically ill patients: a structured review 
2.1 Synopsis 
The aim of this chapter is to review the potential PK changes of antimicrobials in obese 
critically ill patients. In this chapter, various antimicrobials that are commonly used in the 
intensive care unit (ICU) will be explored and the implications for appropriate dosing of 
these agents will be reviewed. 
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2.1.1 Published manuscript entitled “The effect of obesity on the pharmacokinetics 
of antimicrobials in critically ill patients: a structured review 
The manuscript entitled “The effect of obesity on the pharmacokinetics of antimicrobials in 
critically ill patients: a structured review” has been accepted for publication by the 
International Journal of Antimicrobial Agents (2016; 47 (4): 259-68) 
The co-authors contributed to the manuscript as follows: All literature review was 
performed by the PhD candidate, Abdulaziz S Alobaid, under the supervision of Prof Jason 
A Roberts. The PhD candidate, Abdulaziz S Alobaid, took the leading role in manuscript 
preparation and writing. The other co-others contributed data to the analysis as well as 
provided critical review of the final version.   
The manuscript is presented as published; except figures and tables have been inserted 
into the text as slightly different positions and numbers. The numbering of pages, figures 
and tables have been re-arranged to fit overall style of the Thesis. 
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Abstract 
The increased prevalence of obesity presents challenges for clinicians aiming to provide 
optimised antimicrobial dosing in the intensive care unit. Obesity is likely to exacerbate the 
alterations to antimicrobial pharmacokinetics when the chronic diseases associated with 
obesity exist with the acute pathophysiological changes associated with critical illness. The 
purpose of this paper is to review the potential pharmacokinetics changes of antimicrobials 
in obese critically ill patients and the implications for appropriate dosing. We found that 
hydrophilic antimicrobials (e.g. β-lactams, vancomycin, daptomycin) were more likely to 
manifest altered pharmacokinetics in critically ill patients who are obese. In particular for β-
lactams antibiotics, obesity is associated with a larger volume of distribution (Vd). In obese 
critically ill patients, piperacillin is also associated with a lower drug clearance (CL). For 
doripenem, these pharmacokinetic changes have been associated with reduced 
achievement of pharmacodynamics (PD) targets when standard drug doses are used. For 
vancomycin, increases in Vd are associated with increasing total body weight, meaning 
that the loading dose should be based on total body weight even in obese patients. For 
daptomycin, an increased Vd is not considered to be clinically relevant. For antifungals, 
little data exists in obese critically ill patients; during fluconazole therapy, an obese patient 
had a lower Vd and higher CL than non-obese comparators. Overall, most studies 
suggested that standard dosage regimens of most commonly used antimicrobials are 
sufficient to achieve pharmacodynamic targets. However, it is likely that larger doses 
would be required for pathogens with higher minimum inhibitory concentrations.  
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2.2 Introduction  
Obesity is a growing public health concern and is associated with an increased morbidity 
and mortality compared with non-obese individuals.1,2,10 Obesity is a well-known risk factor 
for community and hospital-acquired infection as well as hospital and intensive care unit 
admission.5-7 critically ill obese patients in particular are at a higher risk of infection and 
commonly require antimicrobial therapy.11,12 However, delivering optimal antimicrobial 
therapy in this population is considered to be a great challenge. To date, there are few 
studies summarising the published data and provide clinical guidance for effective dosing 
in these patients.  
Pharmacokinetics (PK) is the study of drug concentration changes in the body over 
time.13,14 It describes drug behaviour in terms of absorption, distribution, and elimination 
which can be mediated by either metabolism or excretion.13 Both volume of distribution 
(Vd)  and clearance (CL) are commonly reported PK parameters that are used to describe 
drug exposure and are used to define drug dosing regimens.13,15 Other PK descriptors of 
relevance include half-life (t1/2), maximum drug concentration (Cmax), minimum drug 
concentration (Cmin) and the area under the concentration curve (AUC).14    
PK modelling is a mathematical approach used to define PK parameters and explain 
changes in drug behaviour between patients. PK modelling can be performed by various 
approaches including a non-compartmental, two-stage, physiologically-based and a 
population PK approach. A non-compartmental analysis does not describe drug disposition 
in terms of distribution into specific compartments, but rather considers the whole body as 
one compartment. A non-compartmental analysis is performed using standard equations 
and is considered a basic form of PK analysis. In the two-stage approach, which is also 
known as the individual parameter estimates approach, two stages are used for PK 
analysis. In Stage 1, PK parameters are estimated for each individual and in Stage 2, the 
dispersion and central tendency of the PK parameters are described according to mean 
(standard deviation) or median (interquartile range) as appropriate. In a two-stage PK 
approach, outlying PK values in a small sample can mean that the observed results are 
not be representative of the actual patient population’s PK estimates. The physiologically-
based PK approach uses software to describe drug distribution into relevant biological 
compartments based such as lung, adipose tissues, and muscles. This latter approach is 
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typically used in laboratory-based studies in early drug development, typically with animal 
models, to accurately characterise drug distribution into different tissues. 
The population PK approach describes the inter- and intra-individual variability of PK. The 
population PK technique is considered to be useful for guiding dose optimization. Some of 
the advantages of the population PK approach include, lower number of samples are 
required to characterize drug behaviour, inter- and intra-variability can be described and 
flexible study designs can be accommodated during the modelling process.               
Understanding antimicrobial pharmacokinetic behaviour is crucial to optimise antimicrobial 
therapy for critically ill obese patients. However, antimicrobial pharmacokinetics is often 
altered by the pathophysiology associated with critical illness16,17 and may be further 
changed in the presence of obesity. Both antimicrobial volume of Vd and CL can be highly 
variable in critically ill and obese patients.18,19 Standard dosage regimens of antimicrobials, 
particularly those that are mainly eliminated through the kidneys, may result in fluctuations 
of plasma concentrations in critically ill patients that may require dosing regimen 
adjustments to ensure optimal antimicrobial concentrations are achieved.20  
Pharmacodynamics (PD) is related to PK and describes the relationship between the drug 
exposure and its pharmacological effect.13 Antimicrobial PD links the antimicrobial 
concentrations with their ability to kill or inhibit the growth of microorganisms.13 To enable 
optimised antimicrobial dosing in the ICU, an understanding of antimicrobial 
pharmacokinetics/pharmacodynamics (PK/PD) and possible PK changes caused by 
critical illness is required. 
2.2.1  Pharmacokinetics and pharmacodynamics overview of antimicrobials 
Antimicrobials can be categorized into three PK/PD classes, according to the relationship 
between drug exposure, pathogen susceptibility and clinical response to antimicrobial 
therapy:21,22  
• time-dependent antimicrobials: the time that the free (unbound) concentration of the 
antimicrobial remains above the minimal inhibitory concentration (fT>MIC) drives 
bacterial killing 
• concentration-dependent antimicrobials: the ratio of the peak antimicrobial 
concentration to MIC (CMAX/MIC) drives bacterial killing; and 
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• concentration-dependent antimicrobials with time dependency: the ratio of the area 
under the concentration-time curve (AUC) of the antimicrobials from 0-24 h to the 
MIC (AUC0-24/MIC) drives bacterial killing. 
2.2.2 Possible antimicrobial PK alterations in critically ill patients 
Significant physiological changes occur in critically ill patients, resulting in elevated cardiac 
output, fluid shifts and/or changes in hepatic or renal function.23 These changes will result 
in changes in Vd, protein binding and drug CL, thus resulting in altered antimicrobial 
pharmacokinetics. 
2.2.2.1 Drug distribution 
Significant cardiovascular changes can commonly cause Vd alterations in critically ill 
patients, in particular, in patients with sepsis where endothelial dysfunction and capillary 
leak can occur.16 These processes can increase fluid shifts from the vascular system into 
the interstitial space, possible resulting in lower than usual concentrations of hydrophilic 
antimicrobials (e.g. β-lactams and aminoglycosides). Fluid resuscitation can further 
aggravate this phenomenon.     
2.2.2.2 Protein binding 
A decrease in plasma albumin concentration (hypoalbuminemia) occurs in ca. 40% of 
critically ill patients, 24 and is associated with altered protein binding. As a result, a higher 
unbound concentration of antimicrobials may initially be seen, leading to increased drug 
distribution from the intravascular to the extravascular compartment, thereby increasing 
Vd. Furthermore, the higher unbound concentration is available for elimination from the 
body and as such drug CL is often increased as well.25 
2.2.2.3 Drug clearance 
Significant variability in antimicrobial CL is common among critically ill patients.26 
Hydrophilic antimicrobials are mainly eliminated through the kidney, thus CL can be 
decreased in the presence of acute kidney injury (AKI).23 moreover, lipophilic 
antimicrobials, which are mainly metabolized by the liver, may have lower CL in hepatic 
dysfunction, such as acute liver failure (Table 2-1).23  
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Increased drug CL has been described in critically ill patients and has been termed 
augmented renal clearance (ARC), a condition where renal elimination of circulating 
solutes is increased.27,28 ARC is defined as a creatinine clearance (CLCR) ≥ 130 
mL/min/1.73m2. ARC is associated with sub-therapeutic antimicrobial concentrations and 
worse clinical outcomes in critically ill patients receiving standard doses of antimicrobial 
therapy.29 
Given this background of acute PK changes caused by critical illness, the challenge for the 
clinician is how to balance the obesity-related PK effects on antimicrobials on drug dosing 
regimens in obese critically ill patients.  
2.3 Aim  
The purpose of this paper is to review the potential PK changes of antimicrobials in obese 
critically ill patients and the implications for appropriate dosing. 
2.4 Methods  
Studies were identified by searching PubMed and EMBASE databases (January 1970 to 
October 2015). Reference lists from relevant literature were also searched for matching 
papers. The search terms included ‘pharmacokinetics’ or ‘pharmacodynamics’ or ‘PK’ or 
‘PD’; and ‘critically ill’ or ‘intensive care’; and ‘obesity’; and ‘lipopeptides’ or ‘glycyclines’ or 
‘polymyxin’ or ‘oxazolidinone’ or ‘fluoroquinolone’ or ‘glycopeptide’ or ‘aminoglycoside’ or 
‘beta-lactams’ or ‘antifungal’. All studies conducted in adults and written in English that 
described the pharmacokinetics, pharmacodynamics or dosing regimens of antimicrobials 
in critically ill obese and non-obese patients were selected (Figure 2-1).  
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Table 2-1. Physicochemical properties, PK/PD indices, and PK characteristics of antimicrobial agents in both obese and non-obese. 
Physicochemical 
properties 
Example 
antimicrobial 
classes* 
PK/PD PK Differences between Non-obese and Obese Suggested weight-
based dosing metric 
PK 
Parameter  Non-obese  Obese 
 
Li
po
ph
ilic
 
Fluoroquinolones AUC0-24/MIC 
or CMAX/MIC   Vd** Large Increased in obesity 
LBW 
 
Glycylcyclines AUC0-24/MIC  
Oxazolidinones  CMAX/MIC  
CL Primarily hepatic CL 
Increased or decreased CL 
dependent on hepatic 
function 
Macrolides  AUC0-24/MIC  
H
yd
ro
ph
ilic
 
β-lactams fT>MIC 
 
 
LBW or ABW 
Aminoglycosides 
 CMAX/MIC 
Glycopeptides AUC0-24/MIC 
Polymyxins AUC0-24/MIC 
Vd** Small Increased in obesity 
 
CL 
Primarily renal CL, 
variable according to 
renal function 
Increased or decreased CL 
dependent on renal function 
Lipopeptides  CMAX/MIC or 
AUC0-24/MIC    
Fluconazole  CMAX/MIC or 
AUC0-24/MIC  
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CL = clearance; PK/PD = pharmacokinetic/pharmacodynamics; PK = pharmacokinetics; Vd = volume of distribution; fT > MIC = time that 
the free concentration or unbound fraction of the antibiotic remains above the minimal inhibition concentration (MIC); Cmax = peak 
concentration; AUC0-24 = area under the time curve during 24 h; LBW = lean body weight; ABW = adjusted body weight. 
*For some classes, agents of different characteristics may exist (e.g. levofloxacin is more hydrophilic than other fluoroquinolones; 
ceftriaxone and cefazolin have comparatively much higher protein binding than other beta-lactams including meropenem and cefepime). 
** For conceptual reasons, a small Vd is crudely classified to be <0.7 L/kg and a large Vd >0.7 L/kg. 
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Figure 2-1. Flow diagram describing application of inclusion and exclusion criteria to 
identified studies. 
2.5 Possible pharmacokinetics antimicrobial alterations in critically ill obese 
patients  
PK alterations may be further increased in obese critically ill patients where both 
conditions together (obesity and critical illness) may further cause enhanced 
pathophysiological changes (Figure 2-2).       
 
 
Total no of references (n = 718) 
185 full articles reviewed  
Excluded (n = 69) 
References were excluded due to: 
• Non-adult population (n = 30) 
• Review articles (n = 39) 
Articles included in this review (n = 116)  
Excluded after review of title (n = 533) 
• Not PK related studies (n = 148) 
• Not on antimicrobial studies (n = 156) 
• Non critically ill non-obese (n = 229) 
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Figure 2-2. Influence of physiological alteration on antimicrobial PK in critically ill non-obese, critically ill obese and non-critically ill obese 
patients.  
*in normal kidney function, normal to high GFR has related to obesity and may lead to decrease plasma concentrations of renally cleared 
antimicrobials. 30,31 
Critically Ill Non-Obese Patients 
CL 
 
Vd 
Vascular 
Disease 
Low Plasma 
Concentrations 
High Plasma 
Concentration
 
Low Plasma 
Concentration
 
Vd 
No Change in 
Plasma 
 
Increased: 
LBM, Adipose 
Mass, Organ 
 
Increased: 
Kidney size 
Renal blood 
 
CL 
Non-Critically Ill Obese Patients 
CL 
High Plasma 
Concentrations 
Low Plasma 
Concentration
 
Fluid-loading Oedema AKI or RRT 
Normal Renal 
Function 
ARC 
CL 
 
    CL 
      
 
 
Critically Ill Obese Patients 
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CL  = clearance, Vd =  volume of distribution, ARC =  augmented renal clearance, RRT =  renal replacement therapy, AKI = acute kidney 
injury.  
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2.5.1 Effects of obesity on drug distribution 
Obesity is associated with an increase of adipose and lean mass, both of which can affect 
the Vd of hydrophilic and lipophilic antimicrobials.30 Increases in adipose tissue are likely 
to increase the Vd of lipophilic antimicrobials. Increases in lean mass, which may account 
for 20-40% of an individual’s excess body weight32, as well as an increase in blood 
volume33, may increase the Vd of hydrophilic antimicrobials. Furthermore, regional blood 
flow into adipose tissues is estimated at only 5% of cardiac output, whilst lean tissues 
receive ca. 73% of cardiac output.34,35 Therefore, obese individuals may have poorer 
peripheral perfusion, resulting in lower subcutaneous adipose tissue concentrations of 
antimicrobials.35 Oedema combined with fluid resuscitation in critically ill obese patients 
can further increase the Vd of different antimicrobials14 (Figure 2-2). 
2.5.2 Effects of obesity on protein binding 
Changes in protein binding of antimicrobials can either increase or decrease the Vd of 
antimicrobials in obese patients because of increased plasma concentrations of α1-acid 
glycoprotein and free fatty acids.36,37 A positive correlation between α1-acid glycoprotein 
levels and protein binding of vancomycin has been described, but the clinical relevance 
remains unclear.38,39 Also, high concentrations of free fatty acids were associated with a 
significant reduction in the protein binding of cefamandole, dicloxacillin, and 
sulfamethoxazole but with increases in protein binding of benzylpenicillin, cephalothin and 
cefoxitin.37 The implications of these data for altered dosing regimens remains unclear.    
2.5.3 Effects of obesity on drug clearance  
An increase of renal CL has been observed in obese individuals who have normal kidney 
function, most likely due to the increased kidney size and renal blood flow associated with 
obesity.30,31 Whilst this altered physiology may result in lower antimicrobial concentrations, 
higher concentrations may be observed in obese patients with co-morbidities such as 
diabetic nephropathy.  
Obese individuals are more likely to have pathologies that cause hepatic dysfunction, such 
as hepatic steatosis, possibly resulting in decreased drug metabolism. Obesity may also 
have an impact on different hepatic enzyme systems causing increased (e.g. CYP2E1) or 
decreased (e,g, CYP3A4) activity.40  
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2.6 Body size descriptors for classification of obesity 
Many methods for measuring weight and body size have been proposed for accurate 
weight-based antimicrobial dosing in obese patients. These formulas are summarised in 
Table 2-2. Body mass index (BMI) is one of the most commonly used descriptors and has 
been internationally endorsed as a favourable classification of body size by both the US 
National Institutes of Health and World Health Organization.41,42  
For lipophilic antimicrobials, which are extensively distributed into tissues including 
adipose tissues, the most relevant size descriptor for Vd appears to be total body weight 
(TBW).43 In contrast, adjusted body weight (ABW) or lean body weight (LBW) are 
suggested for hydrophilic antimicrobials as these agents have limited distribution to 
adipose tissues.43 However, to date no single size descriptor has been shown to 
accurately correlate with Vd and/or CL of antimicrobials in obese individuals.    
For renally excreted antimicrobials, dosage adjustment for renal impairment remains 
important. Many formulas are available for renal function assessment, such as the 
Modification of Diet in Renal Disease (MDRD), Cockcroft-Gault and Jelliffe equations. In 
fact, Salazar-Corcoran equation was developed specifically for obese patients.44 The 
challenges in estimating CLCR in obese non-critically ill patients were investigated by 
Demirovic et al., 45 who measured 24-hr urinary CLCR in 54 obese patients (BMI ranged 
from 38 to 60 kg/m2). The authors compared their results with estimated CLCR using the 
MDRD, Cockcroft-Gault (using TBW, IBW and ABW) and Salazar-Corcoran equations. 
They found that using the MDRD or Cockcroft-Gault formula with IBW underestimated 
CLCR, whereas using Cockcroft-Gault (with TBW or ABW), and Salazar-Corcoran 
equations overestimated CLCR. However, using LBW or free fat mass (FFM) in the 
Cockcroft-Gault equation provided comparable estimates of CLCR.  No such study in 
critically ill obese patients has been performed to provide guidance for estimation of CLCR. 
In light of the conflicting data and lack of validated approaches to estimating renal function 
in critically ill patients, an 8- or 24-h urine collection is recommended to be the most 
suitable and easily available method to estimate renal function in these patients.44,45 
Alternatively, when other drugs that are predominantly cleared renally are being used in 
these patients and that are subject to therapeutic drug monitoring (TDM) (e.g. 
aminoglycosides, glycopeptides), the measured concentrations of these agents can be 
used to estimate likely drug clearance of other renally cleared compounds.46 
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2.7 Pharmacokinetic/pharmacodynamic alterations of specific antimicrobials in 
critically ill obese patients 
There is a dearth of studies investigating antimicrobial dosing requirements in critically ill 
obese patients. Table 2-3 summarizes the available studies that have investigated the 
pharmacokinetics of commonly used antimicrobials both in obese and non-obese critically 
ill patients. 
2.7.1 β-lactams antibiotics 
β-lactam drugs show time-dependent activity. The optimal PK/PD target for these agents 
in the ICU perhaps is still debatable. However, for severe infection in critically ill patients, 
maintaining unbound concentrations above the MIC for 40-100% of the dosing interval is 
suggested as minimum exposure (40-100% fT> MIC).47  
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Table 2-2. Commonly used body size descriptors. 
Measurement 
method  
Abbreviation Definition Estimation equation 
Body Mass Index  BMI The most commonly used for obesity classification TBW (kg)/Ht (m2)48 
Total Body Weight  TBW The total or actual body weight Observed value (kg) 
Ideal Body Weight IBW 
A body size descriptor that relates height-weight 
combination to mortality for adult men and women.43,49  
M = 49.9 + (0.89 x (Ht (cm)-152.4)50 
Fe = 45.4 + (0.89 x (Ht (cm)-152.4) 
Adjusted Body 
Weight  
ABW 
IBW plus a proportion of the difference between TBW 
and IBW, otherwise known as the dosing weight 
correction factor (DWCF). The DWCF reflects that drugs 
will distribute differently to the excess adipose tissue.   
= DWCF x (TBW-IBW) + IBW 51 
Lean Body Weight  LBW Body weight without adipose tissue 
M = (9270 x TBW)/ (6680 + (216 x BMI))52 
Fe = (9270 x TBW)/(8780 + (244 x BMI)) 
Body Surface Area  BSA Often used to calculate doses in chemotherapy = TBW0.425 x Ht (cm)0.725 x 0.007184 53 
Fat Free Mass  
 
FFM 
Body components involving muscle, bone, organs, and 
extracellular fluids are measured by BIA  
M = (TBW x 0.285) + (12.1 x Ht (m)2)54 
Fe = (TBW x 0.287) + (9.74 x Ht (m)2) 
 
M = male; Fe = female; Ht = Height; DWCF = dosing weight correction factor; Kg = kilogram; m2 = metre square; cm = centimetre; BIA = 
bioelectrical impedance analysis.  
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2.7.1.1 Cefazolin 
Cefazolin is highly protein bound. Thus, altered plasma concentrations can be expected in 
the presence of hypoalbuminaemia.55,56 In a recent study by Roberts et al.,56 the 
pharmacokinetics of cefazolin was described in plasma and the  interstitial fluid of tissues. 
Using a population PK modeling approach, the authors found that patient weight was a 
significant covariate of the volume of distribution of the central compartment (p=0.04), with 
obese patients having larger values compared to the non-obese patients.  
2.7.1.2 Meropenem 
Cheatham et al. concluded that whilst the pharmacokinetics of meropenem is not 
significantly different between obese and non-obese critically ill patients 57, in morbidly 
obese patients a higher Vd compared with non-obese patients was observed (mean = 37.8 
Vs. 21.7-29.3 L)58. Although, standard doses were still sufficient to achieve PK/PD targets 
(50% fT>MIC,) for susceptible pathogens, higher doses or prolonged infusion regimens may 
be required for less susceptible pathogens. Hites et al. analyzed meropenem in obese and 
non-obese critically ill patients and found that both the Vd (40.0 L Vs. 27.9 L) and CL (6.1 
L/h Vs. 4.6 L/h) were not significantly different between the two groups.59 However, lower 
meropenem concentrations were observed in obese patients not receiving continuous 
renal replacement therapy (CRRT). The authors recommended routine TDM for 
meropenem dosing in critically ill obese patients.   
2.7.1.3 Doripenem 
Roberts and Lipman described the pharmacokinetics of doripenem in 31 critically ill 
patients with nosocomial pneumonia, including 7 obese patients60. Patients with different 
weights at various doses were investigated, with higher body weight reducing the 
likelihood of achieving target drug exposures. For example, a 60 kg patient (CLCR = 
100mL/min) receiving 500mg intravenous (i.v.) every 8h, achieved sufficient 
concentrations for pathogens with an MIC of 4 mg/L, whereas for the simulated 135 kg 
patient, this same dosage regimen was only sufficient for pathogens with an MIC of 2 
mg/L. The authors concluded that higher doripenem doses are required in obese 
individuals, at least in the initial phase of treatment. The authors also reported that use of 
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extended infusions permitted adequate pharmacodynamics target attainment, even in 
patients weighing significantly more. 
2.7.1.4 Piperacillin  
In a study by Sturm et al., piperacillin was examined in nine critically ill morbidly obese 
patients (BMI > 40kg/m2)61. All patients achieved the PK/PD target of 100% fT >MIC for 
pathogen with an MIC of 16 mg/L using a piperacillin/tazobactam dose of 4.5 g i.v. every 6 
h. Septic morbidly obese patients in the ICU had a higher piperacillin Vd (31.0 vs. 22.4 L) 
and lower CL (6.0 L/h Vs. 13.7 L/h) compared with non-obese patients. From these data, it 
would appear that piperacillin/tazobactam 4.5 g i.v. 6 h is sufficient to attain the PK/PD 
targets in most critically ill morbidly obese patients, with altered dosing required in patients 
who either manifest ARC or who are infected by less susceptible pathogens.  
Another study by Hites et al. showed both the Vd (29.6 L Vs. 21.3 L, P = 0.068) and CL 
(5.4 L/h Vs. 3.2 L/h, P = 0.093) were not significantly different between critically ill obese 
and non-obese patients59. Even though no differences were observed in piperacillin 
pharmacokinetics between these two groups, the authors suggested that routine TDM 
should be implemented in obese patients because of the inherent unpredictability of 
piperacillin pharmacokinetics in critically ill patients.   
Cheatham et al. also found that obesity impacts piperacillin pharmacokinetics, as they 
found that piperacillin had a numerically higher Vd (33.4 L Vs. 21.8 L) and CL (13.7 L/h Vs. 
8.6 L/h) in obese non-critically ill patients compared with non-obese62. They recommended 
that a higher dose may be required in obese individuals to achieve the PK/PD target of 
50% fT>MIC.  
2.7.2 Glycopeptides  
Vancomycin is commonly used to treat Gram-positive pathogens; the PK/PD target is 
AUC0-24/MIC >400.63 Obesity and increasing TBW is correlated with an increased Vd and 
CL of vancomycin.64,65 As such, it is suggested that the loading dose be calculated based 
on TBW followed by a maintenance dose based on the patients CLCR and according to 
TDM.65 Vancomycin dosing is still uncertain and should be performed with caution where 
larger doses (≥4g/day) may be required because of potential increased risk of 
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nephrotoxicity.66 Such doses are considered necessary in obese patients to achieve 
PK/PD targets.     
2.7.3 Quinolones  
Ciprofloxacin is both concentration-dependent and time-dependent, with clinical efficacy 
best described using an AUC0-24/MIC ratio. Malone et al. studied ciprofloxacin in 10 
critically ill patients including 6 obese patients (BMI = 31-42 kg/m2) who were also 
receiving renal replacement therapy (RRT) 67. Ciprofloxacin CL was highly variable among 
the study patients, ranging from 0.34 to 1.70 mL/min/kg compared with 7-8 mL/min/kg 
reported in patients with normal renal function. The authors found little effect of patient 
weight or BMI on ciprofloxacin Vd and CL.  
The pharmacokinetics of ciprofloxacin was also reported in a case study by Utrup et al. 
who presented a morbidly obese patient (BMI 53.7 kg/m2) and was also receiving CRRT68. 
The pharmacokinetics of the drug in this patient was not different to the pharmacokinetics 
previously reported by Malone et al.67 Utrup et al. recommended that higher doses of 
ciprofloxacin are required for critically ill obese patients infected with pathogens with higher 
MICs.    
2.7.4 Colistin 
Colistin is an antimicrobial with both concentration and time-dependent PK/PD that is 
commonly used to treat multi-drug resistant pathogens, such as Pseudomonas 
aeruginosa.69 The PK/PD index that best describes efficacy for colistin is AUC0-24/MIC.  
In a study by Garonzik et al. of 105 critically ill patients, the authors included TBW as a 
covariate on volume of the central compartment (i.e. blood) from which subsequent 
weight-based loading doses were proposed70. This analysis suggests that obese patients 
are recommended to have larger loading doses than non-obese patients. However, the 
heaviest patient in this study was only 106 kg and so the relevance to even heavier 
patients remains unclear. Three small studies (n= 10, n = 14 and n = 18) were carried out 
in critically ill patients and did not show any relationship between patient weight or BMI and 
colistin pharmacokinetics, possibly due to a lack of statistical power 71-73.  
2.7.5 Antifungals 
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Fluconazole is active against variety of Candida spp., with a PK/PD target of AUC0-24/MIC 
ratio > 25.74 To the best of our knowledge, the PK data of fluconazole in critically ill obese 
patients have been reported in only two case studies. Lopez and Phillips described a 
critically ill morbidly obese patient (BMI = 84 kg/m2) receiving RRT who received a 
fluconazole dosage based on LBW (600 mg). A higher Vd (163.3 L) and CL (3.25 L/h) of 
fluconazole was observed in this patient compared with previous data from critically ill non-
obese patients with acute renal failure (Vd = 65.6 L and CL =1.9 L/h).75,76 This case study 
recommended using LBW for both a loading dose of 12mg/ kg and a 6mg/kg maintenance 
dose. Cohen et al. presented a case report of morbidly obese critically ill patient (BMI = 48 
kg/m2)77 that provided similar results to the report from Lopez and Phillips.  
Micafungin is another commonly used antifungal. The PK/PD index associated with 
maximal activity is reported to be AUC0-24/MIC. In a case report of a morbidly obese 
patient (BMI = 102 kg/m2) who was administered 100 mg i.v. micafungin daily78, the 
patient’s drug plasma concentration at 4h post-dose were reported to be significantly lower 
(2.9 mg/L) compared with those observed in non-obese patients following stem cell 
transplantation (5.5 mg/L).79 In a study by Grau et al. of ten patients, of which only one 
was obese, the micafungin volume of distribution of the central compartment (e.g. blood) 
was associated with increasing TBW80. Weight was found to affect the likelihood of 
achievement of target concentrations in higher MIC pathogens. Although more data are 
needed to confirm what dosing regimens for micafungin should be used in obesity, weight-
based dosing may be considered more accurate in later analyses. 
2.7.6 PK data of other antimicrobials in non-critically ill obese patients 
Currently, there are few PK studies that examining the effect of obesity on the 
pharmacokinetics of some drugs in non-critically ill patients.81 Most of these studies have 
agreed that obesity is likely to affect the pharmacokinetics of many drugs. However, to our 
knowledge there are no available PK data in critically ill obese patients for commonly used 
drugs, such as the aminoglycosides, daptomycin and most quinolones. Where no data are 
available, the principles of higher loading dosage regimens to reach target concentrations 
more rapidly followed by doses based on organ function (e.g. CLCR for renally cleared 
drugs) and use of TDM where available should be used. 
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2.8 Limitations 
The studies available for inclusion in this structured review have limitations. The number of 
critically ill obese patients who were included in these studies is generally small, with some 
drugs only having case studies available. Most of the studies compared antimicrobial 
pharmacokinetics of data obtained from critically ill obese patients with historical non-
obese healthy volunteers and patients. Many data are analysed based on only a single 
dose rather than multiple doses, meaning that changes in pharmacokinetics over time 
cannot be described. Finally, there is not a consistent approach with use of the body size 
descriptors in the various studies and this may lead to different recommendations for the 
same drug from different authors. 
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Table 2-3. Characteristics of the available studies reporting on pharmacokinetics of the most commonly used antimicrobials in the ICU. 
 Class name Author, Year   Study design  
No of patients Investigated 
drug(s) PK results obese Non-obese 
β-
la
ct
am
s 
Hites, 2013  Retrospective 49 59 
Meropenema-1  
Vd (L) ob = 40.0 (8.0-191.0); n-ob = 27.9 (5.4-205.2); 
(p = 0.10) 
CL (L/h) ob = 10.1 (1.6-29.3); n-ob = 6.1 (2.1-16.5); (p 
= 0.21) 
Piperacillina-1 
Vd (L) ob = 29.6 (14.3-51.3); n-ob = 21.3 (1.3-165.7); 
(p = 0.068) 
CL (L/h) ob = 10.0 (1.9-15.9); n-ob = 5.1 (1.3-34.4); (p 
= 0.529) 
Cefepime or 
Ceftazidimea-1 
Vd (L) ob = 24.0 (15.3-149.2); n-ob = 21.4 (13.1-48.9); 
(p = 0.488) 
CL (L/h) ob = 4.4 (0.4-10.5); n-ob = 3.0 (0.1-9.1); (p = 
0.965) 
Rich, 201282  Prospective 10 - Cefepime a-1   
Vd (L) ob = 24.6 (15.5-38.1) 
CL (L/hr) ob = 9.1 (6.2-14.5) 
Sturm, 2014 Prospective 9 - Piperacillina-2  
Vd (L) ob = 31.0 ± 9.0 
CL (L/hr) ob = 6.0 ± 1.6 
Cheatham, 2013 Prospective  14 - Piperacillin a-2  
Vd (L); ob = 33.4 ± 14.0 
CL (L/hr) ob = 13.7 ± 5.2 
Alobaid et al, 201583  Retrospective 
246 673 Piperacillina-3  Trough concentration (mg/L) ob= 29.4 (17.0-58.0); n-ob = 42.0 (21.5-73.5); (p = 0.001) 
134 347 Meropenema-3  Trough concentration (mg/L) ob = 10.3 (4.8-160); n-ob = 11.0 (4.3-18.5); (p = 0.296) 
Chen, 200684 Prospective  20 10 Ertapenema-2  
Vd (L/kg) ob = 6.0 ± 1.0; n-ob = 5.2 ± 0.6; (p ≤ 0.05) 
CL (L/h) ob = 1.8 ± 0.3; n-ob = 1.6 ± 0.3; (p ≤ 0.05) 
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Cheatham, 2014 Prospective 9 - Meropenem a-2  
Vc (L) ob = 13.3 ± 6.7; Vss (L) = 37.4±14.7 
CL (L/h) ob = 10.2 ± 5.0 
Roberts, 2013  Prospective 7 24 Doripenema-2  
Vc (L) = 24.4; Vp (L) = 20.9 
CL (L/h) = 20.4 
Am
in
og
ly
co
si
de
s 
Ross, 201385 Retrospective  31 - 
Gentamicin or  
Tobramycin  
71% of the study patients achieved an appropriate 
plasma drug concentration, 13% were found to be 
supra-therapeutic, and 16% sub-therapeutic. 
Taccone, 201086  Prospective  9 65 Amikacina-3  
Vc (L) = 0.23 [0.18-0.28]; Vp (L) =0.18 [0,11-0.23] 
CL* (mL/min/kg) = 1.98 (1.28-3.54) 
Pai, 201187 Prospective  
91 405 Tobramycin  
Vss* (L/kg); ob = 0.30 ± 0.11; n-ob = 0.35 ± 0.11; (p ≤ 
0.008)  a-2 
CL (L/h)= 3.9 [0.4-14.1]  a-3 
298 1237 Gentamicin 
Vss* (L/kg) ob = 0.27 ± 0.10; n-ob = 0.35 ± 0.11; (p ≤ 
0.008)  a-2 
CL (L/h)= 4.2 (0.7-15.8)  a-3 
G
ly
co
pe
pt
id
es
 
Blouin, 1982 88 Prospective  6 4 Vancomycina-2 
Vc (L) ob = 6.40 ± 3.17; Vp (L) = 50.1±11.4; Vss (L) = 
43.0 ± 9.9; Vc (L); n-ob = 7.70 ± 2.17; Vp (L) = 33.2 ± 
3.4; Vss (L) = 28.9 ± 3.6 
CL (L/h); ob = 11.3 ± 3.9; n-ob = 1.1 ± 0.7 
Fl
uo
ro
qu
in
ol
on
es
 Kees, 2011
89 Prospective  12 - Moxifloxacina-2  
Vss (L) = 165 ± 30 
CL (L/h)= 9.6 ±2.0 
Cook, 201190 Prospective  15 4 Levofloxacina-2 
Vd(L) ob = 83.8 ± 21.6; n-ob = 106 ± 12 
CL (L/h) ob = 9.8 ± 4.2; n-ob =11.2 ± 0.3 
Pai, 201491 Prospective  68 - Levofloxacina-2  
p.o: Vc/F (L) = 71.9 ± 25.5 
p.o: CL/F (L/h) = 9.24 ± 5.33 
iv: Vc (L) = 60.8 ± 18.6 
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iv: CL (L/h) = 6.01 ± 4.84 
Utrup, 2010 Case study 1 -  Ciprofloxacina-4  
Vss (L) = 90 
CLs (L/h) = 8.3 
Higher dose is required to achieve the PK/PD target in 
critically ill patients receiving CVVHDF 
Allard, 199392 Prospective  17 11 Ciprofloxacina-2  
Vss (L) ob = 269.17 ± 51.64; n-ob = 219.03 ± 35.80 
CL (L/h) ob = 53.8 ± 9.6; n-ob = 44.7 ±7.2 
O
xa
zo
lid
in
on
es
 
Bhalodi, 201293 Prospective  20 6 Linezolida-2 
Vd (L) ob = 24.35 ± 9.39; n-ob = 46.0 ± 11.2 
CL (L/h) ob = 7.61 ± 1.82; n-ob = 8.28 ± 2.32 
G
ly
cy
lin
es
 
Pai, 201494 Prospective  8 4 Tigecycline 
No plasma concentration differences difference 
between ob and n-ob patients (Median concentration 
at 12 hr; ob = 105.4µg/mL; n-ob = 119.2 µ /mL) 
Li
po
pe
pt
id
es
 
Dvorchik, 200595 
 
 
 
Prospective  13 12 Daptomycina-4  
Vss (L) ob = 7.90 (10.28); n-ob = 6.35 (11.42); (P = 
0.009) 
CL (L/h) ob = 0.5 (0.2); n-ob = 0.4 (0.7) (P = 0.098) 
Vss (L) m-ob = 10.68 (15.3); n-ob = 6.74 (17.22); (P = 
0.004) 
CL (L/h) m-ob = 0.5 (0.03); n-ob = 0.4 (0.-3)) (P = 0.09) 
Pai, 200796 Prospective  7 7 Daptomycina-2   Vd (L) m-ob = 10.04 ± 2.04; n-ob = 7.69 ± 1.05 (p= 0.07) 
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CL (L/h); m-ob = 0.82 ± 0.21; n-ob = 0.73 ± 0.14 (p = 
0.34) 
An
tif
un
ga
ls
 
Cohen et al, 1997  Case study 1 Historical data  Fluconazole 
Plasma concentrations ob = 23.9 mg/L; n-ob = 51.8 
mg/L 
CL (L/h) ob = 8.4, n-ob 1.3 
Lopez and Phillips. 2014 Case study 1 Historical data Fluconazole 
Vd (L) ob 163.32; n-ob = 65.57 
CL (L/h) ob = 3.25; n-ob = 1.90 
Zomp et all, 2011 Case study 1 Historical data Micafungin Plasma concentration (mg/L) ob = 2.9; n-ob ≈ 5.5. 
 
Data are described as follows: a-1 mean (range); a-2 mean±SD; a-3 median [IQR]; a-4 mean (% coefficient of variation)  
ABW = adjusted body weight; AUC = area under the concentration curve; CL = clearance; CVVHDF = continuous venovenous 
hemodiafiltration; i.v = intravenous; LBW = lean body weight; MIC = minimum inhibitory concentration; m-ob = morbidly obese; n-ob= 
non-obese; ob = obese; PD = pharmacodynamics; PK = pharmacokinetics; p.o = oral route; Vc = central compartment volume of 
distribution; Vd = volume of distribution; Vp = peripheral compartment volume of distribution; Vss = volume of distribution at steady state; 
TBW = total body weight.    
* Pharmacokinetic parameter reported by body weight (kg) as patient weight data for obese and non-obese patients not reported to report 
absolute values  
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2.9 Conclusions 
Both critical illness and obesity are associated with physiological changes that can alter 
the pharmacokinetics of many antimicrobials. Alterations of antimicrobial pharmacokinetics 
are likely to require dose individualization to enable the achievement of target plasma 
concentrations. Unfortunately, there is a dearth of robust studies that have analysed the 
pharmacokinetics of antimicrobials in critically ill obese patients. Until more robust studies 
become available, for most antimicrobials, daily re-evaluation of doses in critically ill obese 
patients is required. Where possible this should be supported with TDM to ensure effective 
antimicrobial doses are used.  
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Chapter 3. What is the effect of obesity on piperacillin and meropenem trough 
concentrations in critically ill patients  
3.1 Synopsis 
The aim of this chapter is to retrospectively analyse therapeutic drug monitoring data from 
ICU databases in Australia, Germany and Spain as well as from a large pharmacokinetic 
study. In this chapter, the unbound piperacillin and meropenem trough concentrations 
were compared in critically ill patients with different BMI categories. Logistic regression 
was also used to describe factors associated with achievement of the PK/PD targets, an 
unbound concentration maintained above the MIC breakpoint (100% fT>MIC and 100% 
fT>4xMIC) of Pseudomonas aeruginosa. 
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3.2 Published manuscript entitled “What is the effect of obesity on piperacillin and 
meropenem trough concentrations in critically ill patients?” 
The manuscript entitled “What is the effect of obesity on piperacillin and meropenem 
trough concentrations in critically ill patients?” has been accepted for publication by the 
Journal of Antimicrobial Chemotherapy (2015; 71 (3): 696-702). 
The co-authors contributed to the manuscript as follows: All literature review and analysis 
was performed by the PhD candidate, Abdulaziz S Alobaid, under the supervision of Prof 
Jason A Roberts. The PhD candidate, Abdulaziz S Alobaid, took the leading role in 
manuscript preparation and writing. The other co-authors contributed data to analysis as 
well as critical review of the final version.   
The manuscript is presented as published; except figures and tables have been inserted 
into the text as slightly different positions and numbers. The numbering of pages, figures 
and tables have been re-arranged to fit overall style of the Thesis.  
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Abstract 
The objectives of this study were to determine the effects of obesity on unbound trough 
concentrations and on the achievement of pharmacokinetic (PK)/pharmacodynamic (PD) 
targets of piperacillin and meropenem in critically ill patients. This study retrospectively 
analysed therapeutic-drug-monitoring data from intensive care unit databases in Australia, 
Germany and Spain as well as from a large pharmacokinetics study. The presence of 
obesity was defined as a body mass index >30 kg/m2, and patients were also categorised 
based on levels of renal function. The presence of obesity was compared to unbound 
piperacillin and meropenem trough concentrations. We also used logistic regression to 
describe factors associated with the achievement of the PK/PD targets, an unbound 
concentration maintained above the MIC breakpoint (100% fT>MIC and 100% fT>4xMIC) of 
Pseudomonas aeruginosa. In all, 1400 patients were eligible for inclusion in the study. The 
median age and weight were 67 years (IQR 52-76) and 79 (69-90 kg), respectively, and 
65% of participants were male. Significantly lower median piperacillin trough 
concentrations [29.4 mg/L (IQR 17.0-58.0)] were found in obese patients compared to 
non-obese [42.0 (21.5-73.5 mg/L)] (p = 0.001). There was no difference for meropenem 
trough concentrations [obese 10.3 mg/L (IQR 4.8-16.0 mg/L)] versus non-obese 11.0 mg/L 
(4.3-18.5 mg/L); p = 0.296]. Using logistic regression, we found that presence of obesity 
was not associated with achievement of 100% fT>MIC, but the use of prolonged infusion, a 
creatinine clearance ≤ 100 mL/min, increasing age and female gender were for various 
PK/PD targets for both piperacillin and meropenem (p<0.05). This large dataset has 
shown that the presence of obesity in critically ill patients may affect piperacillin, but not 
meropenem unbound trough concentrations.  
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3.3 Introduction 
Beta-Lactam antibiotics, such as meropenem and piperacillin are frequently prescribed in 
critically ill patients.47,97,98 Recent studies have shown that there is considerable variation 
in the beta-lactam pharmacokinetics (PK) in some populations.99-101 Obesity has previously 
been proposed to be a risk factor for altered beta-lactam concentrations in critically ill and 
non-critically ill patients.59,102,103 Consequently, with the increased prevalence of obesity in 
Western society, ensuring therapeutic concentrations of beta-lactam antibiotics in obese 
critically ill patients is considered to be a serious challenge for clinicians.104-107 This is 
because dose-finding studies do not include obese nor critically ill patients, and current 
data for obese critically ill patients show significantly wider variability in the PK of beta-
lactam antibiotics compared to non-obese critically ill patients.59,61 This PK variability 
results from the physiological changes caused by obesity which may alter both the volume 
of distribution and clearance of the drug.108 In the presence of critical illness, these PK 
effects may escalate into augmented renal clearance (ARC) or acute kidney injury 
(AKI).109-111 These changes in drug disposition heighten the challenge of dosing in obese 
critically ill patients.109-111  
We are not aware of any available dosing guidelines for critically ill obese patients.61,112 
Although Hites and Taccone have provided a very useful recent review on the optimisation 
of β-lactam dosing in critically ill obese patients81,  the certainty of the recommendations 
are unclear. In their review, only single-centre small PK studies and case series were 
available, and very few of them compared results from obese patients with those of non-
obese critically ill patients.  
Therefore, the aim of this study was to compare piperacillin and meropenem trough 
concentrations, as well as the achievement of PK/pharmacodynamic (PD) targets in 
critically ill obese and non-obese patients. 
3.4 Methods 
3.4.1 Study design and setting 
This study retrospectively analysed data from therapeutic drug monitoring (TDM) 
databases from three intensive care units (ICUs), the Royal Brisbane & Women’s Hospital, 
Australia; Heidenheim Hospital, Germany; and Hospital del Mar, Spain as well as from the 
  
40 
Defining Antibiotic Levels in Intensive care unit (DALI) multi-centre point-prevalence PK 
study in 68 ICUs.113 In these datasets, blood samples had been collected from critically ill 
patients treated with meropenem and piperacillin. All plasma samples were assayed using 
validated chromatographic methods. In samples from Australia and the DALI Study, 
unbound concentrations were directly measured, whilst in those from Germany and Spain, 
total antibiotic concentrations were measured. For the latter two, unbound concentrations 
were then calculated using protein-binding percentage for piperacillin (30%) and 
meropenem (2%), as recommended by Wong et al.114  
Ethics approval for this study was granted by the Human Research Ethics Committee, 
Royal Brisbane and Women’s Hospital, Brisbane, Australia (HREC/14/QRBW/534).  
Meropenem and piperacillin/tazobactam were dosed according to the treating clinicians’ 
decision. Dosing was administered by either intermittent or prolonged infusion. Prolonged 
infusion was defined as an infusion > 2 h including administration by continuous infusion.  
3.4.2 Patients 
Critically ill patients were included in the study if they met the following inclusion criteria: 
aged ≥ 18 years; body mass index (BMI) ≥ 18.5 kg/m2; treated with meropenem or 
piperacillin; and a complete set of data for all variables. Exclusion criteria were: age < 18 
years; BMI < 18.5 kg/m2; and missing data. Patients were categorised into two BMI 
categories of non-obese (BMI from ≥ 18.5 to 29.9 kg/m2) and obese (BMI ≥ 30 kg/m2). 
Furthermore, patients were categorised according to creatinine clearance (CLCR), which 
was calculated using the Cockcroft-Gault equation, into classes 1 (≤ 25 mL/min), 2  (>25 to 
≤50 mL/min), 3 ( >50 to ≤ 100 mL/min) and 4 (> 100 mL/min).      
Approaches to dosing across the Australian and Spanish groups, as well as the DALI 
study, were similar, with all patients receiving standard dosing for both piperacillin (12-16 g 
per 24 h in 3-4 divided doses) and meropenem (2-3 g per 24 h in 2-3 divided doses). 
However, the patients from Germany received a nomogram derived CLCR-based 
continuous infusion of antibiotic, where CLCR was calculated using the Cockcroft-Gault 
equation with ideal body weight. 
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3.4.3 Data collection 
Demographic and clinical information, including age, sex, height, weight, BMI, serum 
creatinine concentration and unbound trough concentrations for meropenem or piperacillin, 
was extracted from the databases. The duration of antibiotic infusion was also collected. 
CLCR was calculated using the actual body weight the patients.115 The total daily dose of 
the study antibiotics was calculated from the prescribed dose strength and frequency.  
3.4.4 PK/PD target attainment    
To investigate the effect of obesity on PK/PD target attainment, the following PK/PD 
targets were assessed:113,116 
I. 100% of the dosing interval that the unbound concentration of antibiotic is exceeds 
the minimum inhibitory concentration (100% f T>MIC)  
II. 100% of the dosing interval that the unbound concentration of antibiotic is exceeds 
four times higher than the minimum inhibitory concentration (100% f T>4xMIC). 
Although these targets are higher than the PK/PD exposures suggested by in vitro PD 
studies,117 these are common TDM targets for sites using TDM for piperacillin and 
meropenem.3,98 As both agents have anti-Pseudomonal activity, we chose the MIC 
breakpoint for susceptibility from EUCAST for this analysis, meropenem 2 mg/L and 
piperacillin 16 mg/L. 
3.4.5 Statistical analysis 
Continuous variables are expressed as median values and interquartile ranges (IQR), and 
categorical variables are expressed as absolute and relative frequencies. The 
Kolmogorov-Smirnov test was used to test for normality. Linear variables were compared 
using Mann-Whitney U test. Dichotomous variables were compared using Pearson chi-
square test or Fisher’s exact test as appropriate. To describe the factors affecting 
attainment of PK/PD targets, factors with a p value <0.15 by univariate analysis were then 
included in the multivariate analysis. The odds ratios (ORs) and bootstrapped 95% 
confidence intervals (CIs) were obtained using binary logistic regression. All statistical 
analyses were performed using the statistical software package IBM-SPSS statistics 22.0 
(IBM Corp, New York USA). A two-sided p value < 0.05 was considered statistically 
significant.  
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3.5 Results  
3.5.1 Demographic and clinical data  
From the 2,875 patients across the combined datasets, 1400 critically ill patients met the 
inclusion criteria for this study (Figure 3-1). Significant differences were found between the 
obese and non-obese patients for age [65 years (IQR 51-74 years) Vs. 68 years ) IQR 53-
76 years); p=0.040], height [170 cm (IQR 160-177 cm) Vs. 170 cm (IQR 165-176); 
p=0.029], weight [100 kg (IQR 90-115 kg); Vs. 73 kg (IQR 65-80kg); p<0.001], BMI [34 
kg/m2 (IQR 31-39 kg/m2] Vs. 25 kg/m2 (IQR 23-27 kg/m2); p<0.001], serum creatinine 
concentrations [109 µmol/L (IQR 74-189 µmol/L) Vs. 92 µmol/L (IQR 64-157 µmol/L); 
p<0.001] and CLCR [73 mL/min (IQR 42-124 mL/min) Vs. 59 mL/min (IQR 34-99 mL/min); 
p<0.001]. Table 3-1 displays the demographic and clinical factors for all patients that were 
associated with achievement of PK/PD targets. 
 
 
 
 
 
 
 
 
 
 
 
 
  
43 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-1. Study flow chart. 
Total patients (n= 2875) 
Included patients (n= 1400) 
Non-obese (n = 1020); Obese (n = 380) 
 
 
Piperacillin (n= 919) Meropenem (n= 481) 
Excluded patients (n= 1475) 
Reasons for exclusion  
Under age (n = 29) 
BMI< 18.5 kg/m2 (n = 104)  
Unavailability of trough concentration (n = 
81) 
Duplicates, missing data (n = 261) 
Infusion > 2 h (n= 263) Infusion > 2 h (n= 582) Intermittent Bolus (n= 218) Intermittent Bolus (n= 337) 
Non-obese (n = 436) 
Obese (n = 146) 
Non-obese (n = 237) 
Obese (n = 100) 
Non-obese (n = 155) 
Obese (n = 63) 
Non-obese (n = 192) 
Obese (n = 71) 
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Table 3-1. Patient characteristics: demographic and clinical data according to PK/PD 
achievement. 
 
Plasma antibiotic concentration over MIC achievement 
fT> MIC fT> 4xMIC 
Achieved Not achieved P Achieved 
Not 
achieved P 
Age (years) 65.4 46.8 <0.001 70.0 57.3 <0.001 
Male, n (%) 732 (64.4) 180 (68.7) <0.001 394 (58.4) 518 (71.5) <0.001 
Height (cm) 169.9 169.6 <0.001 169.0 172.0 <0.001 
Weight (kg) 81.2 80.0 0.055 78.1 85.0 <0.001 
BMI (kg/m2) 28.1 28.0 0.965 27.7 28.8 0.032 
Meropenem, n (%) 404 (84.0) 77 (16.0) 
0.034 
297 (61.7) 184 (38.3) 
<0.001 
Piperacillin, n (%) 733 (79.8) 185 (20.2) 378 (41.2) 540 (58.8) 
Serum creatinine 
concentration (µmol/L) 140 58.2 <0.001 181.2 100.3 <0.001 
CLCR (mL/min); estimated by 
Cockcroft-Gault equation  72.6 161.5 <0.001 48.4 104.3 <0.001 
3.5.2 Dosing and concentration data  
Table 3-2 presents the total daily dose and unbound trough concentration data comparison 
between obese and non-obese patients. Of the patients categorised as receiving 
prolonged infusion, 226/263 (86%) meropenem patients and 538/582 (92.4%) piperacillin 
patients received continuous infusions. No significant differences between the BMI groups 
were found for the total daily dose or duration of infusion for either piperacillin or 
meropenem. Significantly lower trough concentrations were found for piperacillin in the 
critically ill obese patient group.  
3.5.3 Differences in trough concentration between obese and non-obese patients  
Table 3-3 shows the differences in trough concentrations between obese and non-obese 
critically ill patients relative to duration of infusion and the different CLCR classes. No 
significant differences in trough concentrations between the obese and non-obese groups 
were found. 
3.5.4 PK/PD target achievement  
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Table 3-4 presents the piperacillin and meropenem data for the achievement of PK/PD 
targets. There was no significant different between obese and non-obese patients for 
achievement of fT>MIC for either antibiotics. A significantly lower percentage of obese 
patients achieved fT>4xMIC for piperacillin, although the frequency of target attainment was 
low for both obese and non-obese patients.  
3.5.5 Factors predicting fT>MIC and fT>4xMIC.  
The factors that predicted the achievement of the PK/PD targets (fT>MIC and fT>4xMIC) are 
shown in Table 3-5. We found that prolonged infusion, a CLCR ≤ 100 mL/min, greater age 
and female gender were all associated with the achievement of fT>MIC for piperacillin. 
Higher total daily dose, CLCR ≤ 100 mL/min and female gender were associated with the 
achievement of fT>4xMIC for piperacillin. Prolonged infusion, CLCR > 50 to ≤ 100 mL/min, 
and greater age were associated with the achievement of fT>MIC for meropenem, whereas 
prolonged infusion, a CLCR ≤ 100 mL/min, greater age and female gender were all 
associated with achievement of fT>4xMIC. The presence of obesity was not a significant 
factor associated with the achievement of the chosen PK/PD targets for either antibiotic. 
3.6 Discussion  
There is a dearth of large studies describing the effect of obesity on β-lactam 
concentrations and PK/PD target achievement in critically ill patients. In our study, we 
found that patients classified to be obese (BMI ≥ 30 kg/m2) had lower unbound trough 
concentrations for piperacillin, but not meropenem, than those of non-obese patients. We 
observed that 23.7% and 14.2% of obese patients did not achieve 100% f T>MIC for 
piperacillin and meropenem, respectively, whearas this target was not achieved in 19.8% 
and 16.7% respectively, of non-obese patints. For a higher PK/PD target of 100% f T>4xMIC, 
only piperacillin was associated with a significantly lower target attainment in the obese 
group, although target attainment was low for both obese and non-obese patients. These 
results of our study do not align with the findings of the only other similar study of critically 
ill patients comparing obese and non-obese patients. In that study, by Hites et al.,59 
meropenem concentrations were found to be lower in obese than in non-obese critically ill 
patients, with no significant differences found for piperacillin between these two groups. 
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Table 3-2. Total daily doses, duration of infusion and unbound trough concentration data for piperacillin and meropenem for obese and 
non-obese groups. 
 
The p value tested the significance of difference between the obese and non-obese patients. 
 
 
  
 Piperacillin Meropenem 
 
All patients 
(n = 919) 
Obese 
(n = 246) 
Non-obese 
(n = 673) 
p 
All patients 
(n = 481) 
Obese 
(n = 134) 
Non-obese 
(n = 347) 
p 
Total daily dose (g), median (IQR) 
12.0 
[8.0-16.0] 
12.0 
[12.0-16.0] 
12.0 
[8.0-16.0] 
0.126 
3.0 
[2.0-3.0] 
3.0 
[2.0-3.0] 
3.0 
[2.0-3.0] 
0.248 
Method of infusion, n (%)   
Intermittent bolus 337 (36.7) 100 (40.7) 237 (35.2) 
0.130 
218 (45.3) 63 (47.0) 155 (44.7) 0.643 
Prolonged infusion 582 (63.3) 146 (59.3) 436 (64.8) 263 (54.7) 71 (53.0) 192 (55.3) 
Trough concentration (mg/L)), median 
(IQR)  
38.5 
[19.7-70.0] 
29.4 
[17.0-58.0] 
42.0 
[21.5-73.5] 
0.001 
11.0 
[4.4-17.5] 
10.3 
[4.8-16.0] 
11.0 
[4.3-18.5] 
0.296 
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Table 3-3. The effects of obesity on piperacillin and meropenem unbound trough concentrations according to duration of infusion and 
CLCR for prolonged infusion versus intermittent bolus. 
 Piperacillin Trough Concentration (mg/L) Meropenem Trough Concentration (mg/L) 
Dosing methods 
 
All patients Obese Non-obese  All patients Obese Non-obese  
Prolonged infusion (n = 576) (n = 144) (n = 432) p (n = 260) (n = 71) (n = 189) p 
C
L C
R
  C
la
ss
es
 (m
L/
m
in
) CLCR <25  
(n = 118)  
106 [72-140] 
(n = 24)  
78 [54-154] 
(n = 94)  
107 [78-137] 
0.494 
(n = 45)  
21 [15-27] 
(n = 9)  
16 [9-28] 
(n = 36)  
22 [16-27] 
0.626 
CLCR >25 to 
≤50  
(n = 147)  
84 [58-116] 
(n = 28)  
76 [48-104] 
(n = 119)  
85 [60-116] 
0.309 
(n = 75)  
18 [15-25] 
(n = 19)  
16 [15-20] 
(n = 56)  
19 [16-27] 
0.365 
CLCR > 50 to ≤ 
100  
(n = 211)  
57 [40-83] 
(n = 52)  
49 [32-79] 
(n = 159)  
59 [43-84] 
0.608 
(n = 75)  
15 [10-18] 
(n = 21)  
15 [12-18] 
(n = 54)  
15 [10-18] 
0.765 
CLCR >101  
(n = 100)  
35 [26-51] 
(n = 40)  
34 [27-47] 
(n = 60)  
39 [25-55] 
0.555 
(n = 65)  
8 [4-12] 
(n = 22)  
8 [5-12] 
(n = 43)  
8 [3-12] 
0.491 
Intermittent bolus (n = 332) (n = 99) (n = 233) p (n =209) (n = 60) (n = 149) p 
C
L C
R
  C
la
ss
es
 (m
L/
m
in
) CLCR <25 
(n = 31)  
103 [48-141] 
(n = 6)  
79 [40-108] 
(n = 25)  
112 [57-162] 
0.478 
(n =17)  
12 [10-17] 
(n = 2)  
10 [10-10] 
(n = 15)  
13 [10-17] 
0.592 
CLCR >25 to 
≤50 
(n = 63)  
47 [16-90] 
(n = 18)  
69 [15-100] 
(n = 45)  
44 [17-84] 
0.568 
(n =51)  
11 [6-15] 
(n = 16)  
13 [8-18] 
(n = 35)  
9 [5-14] 
0.639 
CLCR > 50 to ≤ 
100  
(n = 113)  
21 [10-51] 
(n = 35)  
19 [11-54] 
(n = 78)  
22 [8-51] 
0.447 
(n =58)  
7 [3-14] 
(n = 20)  
7 [3-18] 
(n = 38)  
7 [4-14] 
0.552 
CLCR >100  (n = 125)  (n = 40)  (n = 85)  0.668 (n =83)  (n = 22)  (n = 61)  0.662 
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Data are presented as median [interquartile range] or number (percentage). The p value tested the significance of difference between the 
obese and non-obese patients.   
 
Table 3-4. Piperacillin and meropenem achievement of PK/PD targets. 
Pharmacokinetics/ Pharmacodynamics index  All patients  Obese  Non-obese  p 
Piperacillin 
fT>MIC, n (%) 727 (79.1) 178 (76.3) 540 (80.2) 0.097 
fT>4xMIC, n (%) 259 (28.2) 51 (20.7) 208 (30.9) 0.002 
Meropenem 
fT>MIC, n (%) 404 (84.0) 115 (85.8) 289 (83.3) 0.298 
fT>4xMIC, n (%)  279 (61.7) 80 (59.7) 217 (62.5) 0.566 
MIC = minimum inhibitory concentration. fT>MIC = unbound concentration of antibiotic was maintained above the minimum inhibitory 
concentration. fT>4xMIC = unbound concentration of antibiotic was maintained above four times higher than the minimum inhibitory 
concentration. The p value tested the significance of difference between the obese and non-obese patients.   
 
6 [2-15] 5 [2-18] 7 [2-13] 1 [0-5] 1 [0-5] 1 [0.4-5] 
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Table 3-5. Binary logistic regression of factors predicting fT>MIC and fT>4xMIC. 
Variable Odds ratio (95% CI) 
Factors predicting fT>MIC Piperacillin p Meropenem p 
Method of administration     
Prolonged infusion 
8.39 
(5.35-13.17) 
<0.001 
7.80 
(3.72-16.38) 
<0.001 
Daily dose 
1.07 
(0.98-1.16) 
0.123 
0.86 
(0.72-1.03) 
0.091 
CLCR 0-50 (mL/min)1 
3.53 
(2.11-5.92) 
<0.001 
3.40 
(0.86-13.51) 
0.082 
CLCR 50-100 (mL/min)1 
14.08 
(7.41-27.08) 
<0.001 
21.74 
(6.02-76.92) 
<0.001 
CLCR >100 (mL/min)1 1.00  1.00  
Age (year) 
1.02 
(1.00-1.03) 
0.012 
1.04 
(1.01-1.06) 
0.002 
Gender (male) 
0.43 
(0.28-0.64) 
<0.001 
1.14 
(0.59-2.22) 
0.700 
BMI 
0.77 
(0.52-1.15) 
0.203 
1.29 
(0.62-2.66) 
0.496 
Goodness-of-fit (Hosmer-
Lemeshow test) 
X2 = 11.109, 
df = 8 0.196 
X2 = 2.428, df 
= 8 0.965 
 
Factors predicting fT>4XMIC Piperacillin p Meropenem p 
Method of administration     
Prolonged infusion 
0.70 
(0.42-1.18) 
0.183 
7.31 
(4.32-12.37) 
<0.001 
Daily dose 
1.10 
(1.02-1.20) 
0.021 
1.04 
(0.88-1.23) 
0.665 
CLCR 0-50 (mL/min)1 
5.81 
(3.44-9.80) 
<0.001 
3.44 
(1.86-6.37) 
<0.001 
CLCR 50-100 (mL/min)a 
166.6 
(2.17-
1000.00) 
<0.001 
20.83 
(9.52-45.45) 
<0.001 
CLCR >100 (mL/min)a 1.00  1.00  
Age (year) 0.99 0.639 1.02 0.014 
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(0.98-1.01) (1.00-1.04) 
Gender (male) 
0.29 
(0.19-0.46) 
<0.001 
0.36 
(0.20-0.62) 
<0.001 
BMI 1.00 (0.61-1.64) 0.992 
1.09 (0.64-
1.87) 0.746 
Goodness-of-fit (Hosmer-
Lemeshow test) 
X2 = 9.449, df 
= 8 0.306 
X2 = 5.191, df 
= 8 0.062 
  
CI = confidence interval; fT>MIC = unbound drug concentration exceeds the minimum 
inhibitory concentration of the organism, CLCR = creatinine clearance estimated by 
Cockcroft-Gault equation, fT>4xMIC = unbound drug concentration exceeds four times higher 
than the minimum inhibitory concentration of the organism; BMI = body mass index 
aOR compares creatinine clearance range against creatinine clearance >100 mL/which 
was the reference category.  
The difference between the Hites et al.59 study and those of our study could be due the 
different case mix of the patients from the studies and the different empirical approaches 
to dosing across the respective patient cohorts. The present results are consistent with 
studies of obese cohorts that found both meropenem and piperacillin achieved 100% 
fT>MIC in many patients,57,61,62,103 although we believe that 23.7% of patients not achieving 
the target for piperacillin, in particular, is a value that as clinicians we should aim to 
improve. 
Of interest, the statistical significance of obesity for affecting PK/PD target attainment for 
piperacillin in the univariate analysis was not found to be significant in the logistic 
regression (Table 3-5). The factors associated with achieving the lower PK/PD target, 
100% fT>MIC, for both antibiotics included use of prolonged infusion, a lower CLCR defined 
as ≤ 100 mL/min and increasing age. This result is unsurprising, as use of prolonged 
infusions has been shown in simulation studies to increase fT>MIC, as has the presence of 
reduced renal function, which is also more common in older patients. The daily dose was 
interestingly not found to be associated with achievement of fT>MIC, and this finding may be 
because there was not a wide range of doses used in the study, or, alternatively, because 
the minor dose adjustments that were made for different levels of renal function prevented 
this being significant. For the higher PK/PD target, 100% fT>4xMIC, only a lower CLCR 
defined as ≤ 100 mL/min and female gender were associated with target attainment for 
both antibiotics. In this analysis the use of prolonged infusion was not significant, which 
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emphasizes the fact that this altered method of administration is most effective in patients 
with higher levels of renal function. 
These data suggest that clinicians need to be mindful of patients with elevated CLCR, 
including ARC which is associated with lower trough β-lactam concentrations.118 As 
piperacillin and meropenem, like many other β-lactam antibiotics, are hydrophilic 
compounds and are eliminated by glomerular filtration, ARC is likely to be a highly 
important covariate for dosing. This hypothesis was confirmed from a study by Udy et al.118 
that showed that patients with ARC were significantly more likely to have lower β-lactam 
trough concentration. 
There are some limitations to this study. First, the study retrospectively evaluated previous 
TDM data, and we used only one plasma antibiotic concentration on one day of therapy, 
which was not consistent across the patients. This approach may have reduced the 
reliability of the results because the effects of non-steady-state PK could not be tested. 
This lack of testing may have made it less likely that weight and/or BMI could be shown to 
be associated with PK/PD target attainment, as their effects are likely to be more 
prominent on antibiotic volume of distribution. However the broad inclusion criteria of the 
sample may have mitigated this limitation. Second, the exact timing of the blood sample 
collections could not be guaranteed, which may have reduced the accuracy of the 
concentration results. Third, there were numerous differences in patient characteristics 
between the obese and non-obese patients, whereby the obese patients were generally 
younger and male with a higher calculated CLCR, all factors associated with lower antibiotic 
concentrations.29 The effect of these different patient characteristics on PK/PD target 
attainment was quantifiable in the logistic regression analysis. Fourth, the number of 
patients receiving prolonged infusion of piperacillin in the non-obese group was larger than 
that in the obese group, which may affect the representativeness of the data, although we 
believe that the multivariate analysis approach should overcome any potential confounding 
introduced by having unequal sized groups. Finally, the Cockcroft-Gault equation was 
used in this study to estimate the CLCR, and although this may lead to a less accurate 
estimation of renal function, it is still commonly used clinically to guide therapy.        
3.7 Conclusion 
The combination of critical illness and obesity can produce physiological changes that 
cause significant alterations in renal function and volume of distribution, which can affect 
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concentrations of β-lactam antibiotics. We found that critically ill obese patients who have 
a CLCR > 51 to ≤100 mL/min have lower trough concentrations for piperacillin when the 
antibiotic is administered by prolonged infusion. Consequently, critically ill obese patients 
should receive dosing regimens that aim to achieve therapeutic concentrations that 
increase the likelihood of clinical cure. For some patients receiving piperacillin in particular, 
it appears that a weight-based dose may be needed, although this finding was not 
significant in our logistic regression analysis. However, we are aware that this is a 
retrospective study, and we believe strong conclusions are possible only after a 
prospective study.     
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CHAPTER 4  
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Chapter 4. What is the effect of obesity on the population pharmacokinetics of 
meropenem in critically ill patients? 
4.1 Synopsis 
The aim of this chapter is to prospectively describe the population pharmacokinetics of 
meropenem in a cohort of critically ill patients including obese and morbidly obese 
patients. 
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4.2 “Published manuscript entitled “What is the effect of obesity on the population 
pharmacokinetics of meropenem in critically ill patients?” 
The manuscript entitled “What is the effect of obesity on the population pharmacokinetics 
of meropenem in critically ill patients?” has been accepted for publication by Antimicrobial 
Agents and Chemotherapy (8th April, 2016). 
The co-authors contributed to the manuscript as follows: all literature review and analysis 
was performed by the PhD candidate, Abdulaziz S Alobaid, under the supervision of Prof 
Jason A Roberts. Dr. Steven C. Wallis, Miss Jenny Lisette Ordóñez Mejia, and the PhD 
candidate Abdulaziz S Alobaid were responsible for bioanalysis of meropenem 
concentrations in plasma. Paul Jarrett, Therese Starr, Janine Stuart, Melissa Lassig-Smith 
assisted with obtaining ethical approval to conduct the study and patient consent and 
blood sampling. The PhD candidate, Abdulaziz S Alobaid, took the leading role in 
manuscript preparation and writing. The other co-authors contributed data to the analysis 
as well as critical review of the final version. 
The manuscript is presented as published; except figures and tables have been inserted 
into the text as slightly different positions and numbers. The numbering of pages, figures 
and tables have been re-arranged to fit overall style of the Thesis. The references are 
found alongside the other references of the Thesis, located in ‘Bibliography’.          
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Abstract 
Severe pathophysiological changes in critical illness can lead to dramatically altered 
antimicrobial pharmacokinetics (PK). The additional effect of obesity on PK potentially 
increases the challenge for effective dosing. The aim of this prospective study was to 
describe the population PK of meropenem in a cohort of critically ill patients including 
obese and morbidly obese patients. Critically ill patients prescribed meropenem were 
recruited into three body mass index (BMI) groups, non-obese (18.5-29.9 kg/m2); obese 
(30.0-39.9 kg/m2); and morbidly obese (≥ 40 kg/m2). Serial plasma samples were taken 
and meropenem concentrations were determined using a validated chromatographic 
method. Population PK analysis and Monte Carlo dosing simulations were undertaken with 
Pmetrics®. Nineteen critically ill patients with different BMI categories were enrolled. The 
patient’s mean ± SD age, weight and BMI were 49 ± 15.9 years, 95 ± 22.0 kg and 33 ± 7.0 
kg/m2, respectively. A two compartment model described the data adequately. The mean ± 
SD parameter estimates for the final covariate model were clearance (CL) 15.5 ± 6.0 L/h, 
volume of distribution of the central compartment (Vc) 11.7 ± 5.8 L, intercompartmental 
clearance from central to peripheral compartments 25.6 ± 35.1 L*h-1 and 
intercompartmental clearance from peripheral to central compartment 8.32  ± 12.24 L*h-1. 
Higher CLCR was associated with a lower probability of target attainment with BMI having 
little effect. Although obesity was found to be associated with an increased Vc, dose 
adjustment based on CLCR appears more important than patient BMI. 
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4.3 Introduction 
The prevalence of obesity worldwide has continued to escalate during recent 
decades.119,120 According to data from different organisations, more than two-thirds of 
adults in the USA are overweight or obese, and more than one-third are obese.121,122 
Obesity is thought to be a risk factor for mortality and morbidity in the ICU from different 
type of infections as has been shown for various types of surgical site infections (e.g. 
hysterectomies123, spinal surgery124), community acquired pneumonia11 and peritonitis in 
peritoneal dialysis patients125. Optimised drug dosing is likely to reduce the burden 
associated with infections in these patients, although, there is only sparse data available 
for clinicians to guide antimicrobial dosing in obese patients.      
Dosing in obese critically ill patients is considered highly challenging.4,126 Indeed the 
pathophysiological changes associated with both obesity and critical illness may have 
additive effects on altered pharmacokinetics (PK), although there are very limited 
published data on this topic.23,108 The physiological differences between obese and non-
obese patients include changes in regional blood flow, increased cardiac output as well as 
increased fat and lean mass.127 These changes may alter PK and PK/pharmacodynamics 
(PK/PD) of antimicrobials necessitating dosing adjustment. As the prevalence of obesity 
increases, clinicians more frequently confront the dosing challenges with these patients.  
Meropenem is a broad-spectrum antimicrobial of the carbapenem class,128  which is 
frequently used as empiric or directed therapy in critically ill patients.128 Meropenem shows 
time-dependent anti-bacterial activity. To date, the PK data for meropenem has not been 
well described in critically ill obese patients. In vitro and animal infection model data 
suggest that maintaining unbound concentrations above the MIC for 40% of the dosing 
interval should be considered as a minimum exposure target (40% fT> MIC). It remains 
unclear whether standard meropenem dosing regimens will achieve this target in critically 
ill obese patients.  
The aim of this prospective study was to describe the population PK of meropenem in a 
cohort of critically ill patients including obese and morbidly obese patients.     
4.4 Methods  
4.4.1 Setting 
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This was observational PK study using one interval patient sampling at a tertiary referral 
ICU. Ethic approval was obtained from the local institutional Human Research Ethics 
Committee (HREC/14/QRBW/88). Written informed consent was obtained from all 
participants or from their substitute decision-makers.   
4.4.2 Study population  
The inclusion criteria for this study were: (i) age ≥ 18 years; (ii) receiving meropenem 
(prophylaxis or treatment); and (iii) patient’s body mass index (BMI) ≥ 18.5 kg/m2. The 
exclusion criteria were: (i) patients on renal replacement therapy; (ii) pregnant women; (iii) 
active bleeding patients; or (iv) patients with HIV or hepatitis. 
4.4.3 Study protocol 
Meropenem was administered according to the intensivist decision with a dosage 
regimens of 500 mg, 1 g and 2 g. participants were categorised into three groups 
according to their BMI as follows: non-obese (BMI= 18.5-29.9 kg/m2); Obese (BMI= 30-
39.9 kg/m2); and morbidly obese (BMI ≥ 40 kg/m2). At single occasion (one dosing 
interval), six blood samples were taken from each participant to determine plasma 
meropenem concentrations. Blood samples (about 3 ml) were drawn from the participants 
at the following times: pre-dose, at 30 min (end of infusion), and 45 min, 1, 4 and 8 h after 
dose administration. Other clinical and demographic data were collected on the day of 
plasma sampling that include: age, sex, weight height, and BMI. Clinical data also were 
recorded including SOFA and APACHE II scores; and plasma albumin; serum creatinine 
concentration (Scr).  
4.4.4 Sampling handling, storage and assay 
Collected blood samples were placed in an ice bath immediately and centrifuged at 3000 
rpm for 10 min. Plasma samples were stored at -80°C until bio-analysis. Meropenem 
concentrations in plasma were determined by validated high performance liquid 
chromatography with ultraviolet detection (HPLC-UV) on a Shimadzu Prominence 
instrument. Sample analysis was conducted in batches with calibration standards and 
quality controls in which batch acceptance criteria were applied. Acetonitrile was added to 
a 100 µL aliquot of plasma combined with internal standard (cefotaxime) to precipitate 
proteins.  Following centrifugation, the supernatant was isolated and washed with 
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dichloromethane to remove acetonitrile and lipophilic components. Following 
centrifugation, the upper layer was isolated for chromatographic analysis. The stationary 
phase was a Waters XBridge C18 2.1 x 50 mm column.  The mobile phase was 4% 
acetonitrile / 96% 50 mM phosphate buffer at pH 2.5 delivered isocratically.  The eluent 
was monitored at 304 nm.  
The calibration curve was linear with a weighing of 1/x2 over the range 0.2 to 100 µg/mL. 
The precision and accuracy at the LLOQs were ≤ 5.9%.  The assay was validated against 
matrix effects (precision and accuracy within 4% at high and low concentrations).  The 
assay’s precision and accuracy was determined at both within-day and between-day, and 
was within 6.5% at all three concentrations tested. The assay method was validated for 
linearity, matrix test, selectivity, LLOQ, recovery, reinjection stability and precision and 
accuracy using the FDA criteria for bioanalysis129. 
4.4.5 Population pharmacokinetic modelling 
The plasma meropenem concentrations were fitted to one- and two-compartment models 
using non-parametric adaptive grid (NPAG) algorithm within the Pmetrics package for R 
(Los Angeles, CA, USA) 130,131. Clearance (CL) from the central compartment and 
intercompartmental distribution were modelled as first-order processes.  
Demographic and clinical characteristics that were considered biologically plausible for 
affecting meropenem PK were tested for inclusion as covariates. Data including age, total 
body weight (TBW), ideal body weight (IBW), lean body weight (LBW), sex, BMI, BMI 
categories, Scr, CLCR estimated by Cockcroft-Gault equation (separately using TBW, LBW 
and IBW), albumin, SOFA, APACHE II were tested. Each of these covariates was plotted 
against the PK parameter estimates to assess for correlation. Covariates were retained in 
the model if they showed a significant improvement in the log-likelihood (p<0.05) and/ or 
improved the goodness-of-fit plots.  
4.4.6 Model diagnostics  
The visual prediction check (vpc) of the observed-predicted concentrations scatter plot, the 
coefficient of determination of linear regression of observed-predicted values and the log-
likelihood values from each run were used to evaluate the goodness-of-fit. Predictive 
performance evaluation was based on the mean of both prediction error (bias) and bias-
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adjusted squared prediction error (imprecision) of the population and individual prediction 
model in central compartment.   
4.4.7 Probability of target attainment (PTA)  
Monte Carlo simulations (n = 1000) were performed using Pmetrics software to determine 
the PTA with variety of MICs for CLCR values and BMI classes. Meropenem doses of 500 
mg i.v. 8-hourly as intermittent 30-min infusions or 3 h prolonged infusion, 1000 mg i.v. 8-
hourly intermittent infusion or prolonged infusion and 2000 mg 8-hourly i.v. intermittent 
infusion or prolonged infusion were simulated at three different levels of renal function 
(CLCR = 30, 50 and 150 mL/min) and three BMI categories of non-obese, obese and 
morbidly obese. The PTA for achieving 40% fT>MIC (meropenem plasma concentration 
remains above the MIC for at least 40% of the dosing interval) was calculated for the first 
24 h of therapy (3 doses at 8-hourly). Unbound meropenem concentrations were 
calculated using ptrviouly published data of the free fraction of meropenem (98%)132.    
4.4.8 Fractional target attainment calculation  
MIC data for pathogens that are commonly targeted for treatment with meropenem, 
Acinetobacter baumannii and Pseudomonas aeruginosa, were obtained from the 
European Committee for Antimicrobial Susceptibility and Testing (EUCAST) database 
(available at www.eucast.org) to determine the fractional target attainment (FTA). The FTA 
describes the pharmacodynamic exposure (PTA) of meropenem against an MIC 
distribution. This FTA threshold was achieved when the value exceeded 90%. Susceptible 
MIC distributions of both pathogens (MIC ≤ 2mg/L) were used to determine the FTA for 
directed therapy. Additionally, we determined the FTA for the entire MIC distribution 
(including susceptible and resistant isolate values) to describe dosing during empirical 
therapy.  
4.4.9 Statistical analysis 
Continuous variables are presented as mean (standard deviation) or median (interquartile 
range) as appropriate. Categorical variables are expressed as absolute numbers and 
relative frequencies. The Kolmogorov–Smirnov and Shapiro-Wilk tests were used to test 
for normality.  A one-way analysis of variance (ANOVA) was used to test for differences in 
demographic and clinical data between the BMI categories. Linear regression was used to 
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describe correlations between patient weight metrics in the 3 BMI categories with 
meropenem Vc and CL. All statistical analyses were performed using the statistical 
software package IBM-SPSS statistics 22.0 (IBM, New York, USA). A P value <0.05 was 
considered statistically significant.  
4.5 Results 
4.5.1 Demographic and clinical data 
Nineteen critically ill patients (11 males) were enrolled in the study; seven non-obese, six 
obese and six morbidly obese patients. In total, 112 plasma samples were obtained from 
these patients. The demographic and clinical data of the respective BMI categorisations 
are shown in Table 4-1. Only patients’ weight, BMI and APACHE II score were significantly 
different between the three BMI categorisations (P < 0.05). 
4.5.2 Pharmacokinetic model building 
Meropenem PK was best described by a two-compartment linear model with zero-order 
input of drug into the central compartment (Figure 4-1). Regarding covariates, Cockcroft-
Gault-CLCR (CG-CLCR) was tested where CG-CLCR was calculated using TBW, LBW and 
IBW separately. The CG-CLCR using TBW (normalized to 100 mL/min) for meropenem CL 
improved the model fit best. For meropenem volume of distribution in the central 
compartment (Vc), we applied two categories of BMI (above and below 35 kg/m2) as it 
resulted in a more significant improvement in the model than by using with one or three 
categories. Furthermore, a scaling factor for obesity (O) on Vc in the BMI >35 kg/m2 group 
was included. When these covariates were added, each resulted in a statistically 
significant improvement in the log likelihood from the previous model (P<0.01). The final 
model was as follows:  
I. TVCL = CL* CG-CLCR/100 
II. TVVc = Vc*(BMI/30)0.75  (If BMI <35 kg/m2) 
III. TVVc = Vc*(BMI/38)0.75*O  (If BMI > 35 kg/m2) 
Where CL-CG is the estimated CLCR using the Cockcroft-Gault equation, TVCL is the 
typical value of meropenem clearance, CL is the population parameter estimate of 
meropenem, TVVc is the typical value of meropenem volume of distribution in the central 
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compartment, Vc is the population parameter estimate of the volume of the central 
compartment, and o is a scaling factor for obesity. 
The mean ± SD population pharmacokinetic parameter estimates from the final covariate 
model are shown in Table 4-2. The diagnostic plots to confirm the goodness of fit of the 
model were considered acceptable and are shown in Figure 4-2. The final covariate model 
was then used for Monte Carlo dosing simulations. Figure 4-3 describes the observed 
relationships between Vc and CL with the mean body weights of the three BMI categories. 
None of the measured correlations were statistically significant, although as described in 
our model building process, the inclusion of BMI on Vc improved the goodness of fit plots 
of the model. 
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Table 4-1. Demographic and clinical data (one column for each BMI category). 
 
All Patients  
(n = 19) 
Normal weight patients 
(n = 6) 
Obese patients 
(n = 7) 
Morbidly obese patients 
(n = 6) 
 
Variable Mean (SD) Mean (SD) Mean (SD) Mean (SD) P Value 
      
Age (Year) 49 (15.9) 41 (19.1) 49 (16.2) 58 (7.6) 0.20 
Weight (kg) 95 (22.0)  71 (11.6) 103 (6.8) 109 (23.3)  < 0.01 
Ideal body weight (kg) 65 (12.9) 65 (6.7) 72 (6.3) 55 (17.8) 0.05 
Lean body weight (kg)  60 (13.1) 53 (7.3) 70 (4.7) 55 (17.7) 0.03 
Height (cm) 171 (12.2) 173 (6.0) 177 (7.0) 162 (17.0) 0.07 
Sex (male)* 11 (58) 2 (33) 7 (100) 2 (33) - 
BMI (kg/m2) 33 (7.0) 24 (3.4) 33 (2.2) 41 (1.4) < 0.01 
Scr (µmol/L) 72 (24.0) 62 (26) 89 (20.2) 62 (16.2) 0.05 
CG-TW (mL/min) 151 (62.6) 139 (44.9) 114 (39.3) 206 (66.7) 0.02 
CG-IBW (mL/min) 100 (47.5) 135 (59.9) 80 (30.3) 87 (34.2) 0.07 
CG-LBW (mL/min) 89 (33.5) 107 (40.9) 77 (27.9) 86 (29.2 0.29 
Albumin g/L 26 (6.1) 24 (8.1) 28 (5.1) 24 (4.8) 0.40 
SOFA 6 (3.9) 5 (2.8) 6 (4.9) 6 (3.8) 0.80 
APACHE II 20 (6.9) 26 (3.7) 15 (4.2) 20 (6.9) < 0.01 
 
APACHE II = Acute Physiology and Chronic Health Evaluation; BMI = body mass index; ClCR = measured creatinine clearance; GC-TW = estimated CLCR using 
Cockcroft-Gault equation based on total body weight; GC-IBW = estimated CLCR using Cockcroft-Gault equation based on ideal body weight; GC-LBW = estimated 
CLCR using Cockcroft-Gault equation based on lean body weight; Scr = serum creatinine; SOFA = Sequential Organ Failure Assessment.  
* Data of  male’s gender are presented as number (%).   
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Figure 4-1. Structural PK model for meropenem in critically ill obese and non-obese patients. The model contained volume of distribution 
for the central compartment (plasma; Vc); peripheral compartment (Vp); rate constant for meropenem distribution from the central to 
peripheral compartment (kcp); and rate constant for meropenem distribution from the peripheral to central compartment (kpc).  
 
Meropenem IV dose 
Peripheral compartment Central compartment (Vc) 
kcp 
kpc 
Total clearance (CL) 
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Table 4-2. Parameter estimates for meropenem from the final covariate two compartment 
population pharmacokinetic model. 
 
 Mean (SD) Coefficient of variation (%) Median 
CL (L/h) 15.50 (5.99) 38.8 14.3 
Vc (L) 11.66 (5.75) 49.3 11.1 
KCP (h-1) 25.60 (35.14) 137.2 5.2 
KPC (h-1) 8.32 (12.24) 147.1 3.9 
O 1.43 (0.46) 32.0 1.5 
 
CL = population clearance of meropenem; Vc = population volume of distribution of central 
compartment; kcp = rate constant for meropenem distribution from the central to peripheral 
compartment; kpc = rate constant for meropenem distribution from the peripheral to central 
compartment; O = scaling factor for obesity.  
4.5.3 Dosing simulations 
Monte Carlo simulations and PTA for achieving 40% fT>MIC for various meropenem doses 
are presented in Table 4-3. The results showed that an increasing CLCR was associated 
with a lower PTA for different BMI categories. Furthermore, at the high CLCR 150 mL/min, 
the intermittent dosing regimens of 500 mg and 1000 mg consistently failed to achieve the 
PK/PD target for a MIC of 2mg/L in almost all BMI groups.  
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Figure 4-2.  Diagnostic plots for the final population pharmacokinetic covariate model. (a) Observed meropenem concentrations versus 
population predicted meropenem concentration (R2 = 0.814). (b) Observed meropenem concentrations versus individual predicted 
meropenem concentration (R2 = 0.987). (c) Visual predictive check. 
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Figure 4-3. (Left panel) Relationship of meropenem clearance to the mean (SD) body weight of the BMI categorisations (Clearance 
versus body mass index linear regression r2 0.4915) (Right panel) Relationship of volume of distribution of the central compartment (Vc) 
to the mean (SD) body weight of the pre-specified body mass index (BMI) categorisations (non-obese, obese and morbidly-obese; Vc 
versus body mass index linear regression r2 0.4961).  
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In contrast, all prolonged infusion doses as well as intermittent infusions of 2000 mg 
achieved PK/PD targets up to a MIC of at least 2 mg/L.       
4.5.4 Fractional target attainment  
The FTA for different simulated dosing regimens and patient BMIs and CLCR for both 
directed and empirical coverage of A. baumannii and P. aeruginosa is shown in Table 4-4.  
For empirical therapy, meropenem at 500 mg 8-hourly intermittent or prolonged infusion 
failed to achieve 90% coverage of A. baumannii in all groups of BMI at different level of 
CLCR. However, as CLCR increases (i.e. CLCR ≥ 50 mL/min), meropenem at 500 mg 8-
hourly intermittent or prolonged infusion also failed to achieve 90% coverage of P. 
aeruginosa. Using higher meropenem doses of 2000 mg 8-hourly as prolonged infusion 
enabled coverage of ≥90% or more of P. aeruginosa in all groups of BMI at different levels 
of CLCR. However, this higher dose of meropenem failed to achieve 90% coverage of A. 
baumannii in obese and morbidly obese patients at CLCR level of 150 mL/min or greater.  
For directed therapy, meropenem at 500 mg 8-hourly intermittent infusion failed to achieve 
90% coverage of A. baumannii and P. aeruginosa when CLCR is 150 mL/min or higher. 
Using a dose of 500 mg 8-hourly of meropenem as prolonged infusion or use of an 
increased dose (i.e. at 1000 mg and 2000 mg) enabled coverage of ≥90% or more of A. 
baumannii and P. aeruginosa in all groups of BMI at different levels of CLCR. 
4.6 Discussion  
To the best our knowledge, this is the first prospective population PK study of meropenem 
in morbidly morbidly obese, obese and non-obese critically ill patients. We found that BMI 
was a significant covariate describing meropenem Vc, but when included in dosing 
simulations, the presence of different BMI’s did not greatly affect PK/PD target attainment. 
Importantly, we observed that a higher CLCR (≥ 150 mL/min) was associated with a lower 
achievement of PK/PD targets for all patients. Whilst standard dosing regimen achieved 
PK/PD targets for patients with low and normal kidney function.  
As with antibiotics studies, the susceptibility of the pathogen is of paramount importance to 
effective drug therapy. In this case, we evaluated the fractional target attainment against 
susceptible MIC distributions of A. baumannii and P. aeruginosa as are encountered as 
part of directed therapy. We found, that in almost all dosing scenarios, that meropenem 
achieved PK/PD targets successfully, with the exception of lower doses in the presence of 
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high CLCR (>150 mL/min). This suggests that when used for directed therapy against 
pathogens with a MIC < 2mg/L, dose adjustment is rarely necessary. However, when 
meropenem is used as part of empiric therapy before the susceptibilities of the pathogens 
are known, depending on local susceptibility patterns, in the case of possible A. baumannii 
and P. aeruginosa, higher doses and/or use of prolonged infusion should be considered 
until the pathogen and susceptibility have been characterised.       
At higher CLCR (≥150 mL/min) in critically ill patients in all BMI groups, meropenem 
intermittent dosing regimens consistently failed to achieve PK/PD targets. This failure 
could be remedied by adjusting either the dose or the duration of infusion. Specifically, 500 
mg or 1000 mg 8-hourly meropenem did not achieve PK/PD target for the EUCAST 
breakpoint for A. baumannii and P. aeruginosa of MIC of 2 mg/L. When the doses were 
escalated to 2000 mg 8-hourly, the PK/PD target was achieved. Similarly, when 
meropenem was administered as a prolonged infusion (3 h), PK/PD target achievement 
increased significantly, even for lower doses of 500 mg 8-hourly. This finding is not new for 
meropenem in critically ill patients, but it is novel in the context of the range of BMIs 
investigated in this study.   
Of all the patient characteristics tested in this study, CLCR had by far the greatest influence 
on achievement of PK/PD targets for meropenem. Even increasing BMI, which has been 
proposed to likely be associated with reduced meropenem PK exposures, had far less 
overall effect than CLCR. BMI’s effect was described in our model as being associated with 
changes in the Vc which may indicate altered concentrations are most likely in early 
dosing intervals, but will be irrelevant thereafter when dosing should be performed only 
based on CLCR. Interestingly, BMI as shown in Figure 4-3 was not well correlated with 
meropenem CL or Vc. Other weight descriptors were also not correlated highlighting the 
variable effect that increasing body weight has on meropenem PK. 
A recent retrospective study of 1400 patients evaluated the effect of obesity on the 
unbound plasma concentrations of piperacillin and meropenem.83 For meropenem, the 
presence of obesity did not significantly affect unbound concentrations. The authors used 
logistic regression to demonstrate that dosing based on CLCR was the strongest predictor 
of therapeutic concentrations in critically ill patients including the obese (OR 21.74, 95% CI 
6.02-76.92). Another study retrospectively evaluated the PK of broad-spectrum β-lactam 
antibiotics, including meropenem, in critically ill obese and non-obese patients.
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Table 4-3. Meropenem probability of target attainment (drug concentrations remain above the MIC for 40% of the dosage interval to 
achieve bactericidal activity) at different BMI, CLCR, and dosage regimens and method of administrations. 
      MIC* (mg/L) 
BMI (kg/m2) 
Dose- 
q8h 
CLCR (mL/min) 0.5 1 2  4 8 16 
18.5-29.9  
50
0 
m
g 
II 
30 + + + + - - 
50 + + + + - - 
150 - - - - - - 
30-39.9  
30 + + + + - - 
50 + + + + - - 
150 - - - - - - 
≥40  
30 + + + + - - 
50 + + + + - - 
150 + - - - - - 
18.5-29.9  
50
0 
m
g 
PI
 
30 + + + + - - 
50 + + + + - - 
150 + + + - - - 
30-39.9  
30 + + + + - - 
50 + + + + - - 
150 + + + - - - 
≥40  
30 + + + + - - 
50 + + + + - - 
150 + + + - - - 
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18.5-29.9  
10
00
 m
g 
II 
30 + + + + + - 
50 + + + + + - 
150 - - - - - - 
30-39.9  
30 + + + + + - 
50 + + + + + - 
150 + - - - - - 
≥40  
30 + + + + + - 
50 + + + + + - 
150 + + - - - - 
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BMI (kg/m2) 
Dose- 
q8h 
CLCR (mL/min) 
MIC (mg/L)  
0.5 1 2  4 8 16 
18.5-29.9  
10
00
 m
g 
PI
 
30 + + + + + - 
50 + + + + + - 
150 + + + + - - 
30-39.9  
30 + + + + + - 
50 + + + + + - 
150 + + + + - - 
≥40  
30 + + + + + - 
50 + + + + + - 
150 + + + + - - 
18.5-29.9  
20
00
 m
g 
II 
30 + + + + + + 
50 + + + + + + 
150 + - - - - - 
30-39.9  
30 + + + + + + 
50 + + + + + + 
150 + + - - - - 
≥40  
30 + + + + + + 
50 + + + + + + 
150 + + + - - - 
18.5-29.9  
20
00
 m
g 
PI
 30 + + + + + + 
50 + + + + + + 
150 + + + + + - 
30-39.9  30 + + + + + + 
  
75 
50 + + + + + + 
150 + + + + + - 
≥40  
30 + + + + + + 
50 + + + + + + 
150 + + + + + - 
* Meropenem target MIC was used according to EUCAST breakpoint (2 mg/L)    
BMI = body mass index; q 8h = three times daily dosing; CLCR = creatinine clearance; II = intermittent infusion; MIC = minimum inhibitory 
concentration; IP = prolonged infusion.  
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Table 4-4. Fractional target attainment for various meropenem dosing regimens, CLCR, and BMI. 
 Pathogens 
Acinetobacter baumannii Pseudomonas aeruginosa 
BMI (kg/m2) Dose-q8h CLCR 
(mL/min) 
MIC for 
Directed 
therapy 
MIC for 
Empirical 
therapy 
MIC for 
Directed 
therapy 
MIC for Empirical 
therapy 
18.5-29.9 
50
0 
m
g 
II 
30 98.93% 86.22% 99.02% 90.92% 
50 97.86% 81.64% 98.06% 86.44% 
150 74.31% 57.03% 77.91% 62.90% 
30-39.9  
30 99.15% 85.62% 99.25% 90.52% 
50 98.38% 81.75% 98.54% 86.57% 
150 82.14% 62.98% 85.20% 68.75% 
≥40  30 99.34% 84.70% 99.44% 89.58% 
50 98.69% 81.67% 98.88% 86.46% 
150 87.65% 67.14% 90.06% 72.61% 
18.5-29.9  
50
0 
m
g 
PI
 
30 99.93% 87.66% 99.95% 92.29% 
50 99.89% 84.40% 99.92% 89.28% 
150 99.61% 77.69% 99.73% 81.98% 
30-39.9  
30 99.83% 86.51% 99.87% 91.34% 
50 99.81% 83.53% 99.86% 88.38% 
150 99.25% 76.94% 99.48% 81.27% 
≥40  30 99.72% 85.22% 99.81% 90.03% 
50 99.67% 82.79% 99.77% 87.58% 
150 98.60% 76.14% 99.06% 80.57% 
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18.5-29.9  
10
00
 m
g 
II 
30 99.19% 94.33% 99.24% 96.62% 
50 98.38% 88.62% 98.49% 92.48% 
150 84.58% 67.19% 86.56% 72.37% 
30-39.9  30 99.43% 94.12% 99.48% 96.55% 
50 99.67% 91.84% 99.72% 95.07% 
150 90.77% 72.44% 91.99% 77.36% 
≥40  30 99.63% 92.65% 99.67% 95.61% 
50 99.23% 88.19% 99.32% 92.48% 
150 94.49% 75.81% 95.18% 80.54% 
  
Acinetobacter baumannii Pseudomonas aeruginosa 
18.5-29.9  
10
00
 m
g 
PI
 
30 99.98% 95.72% 99.99% 97.82% 
50 99.97% 91.86% 99.98% 95.29% 
150  99.97% 83.51% 99.98% 88.28% 
30-39.9  
30 99.94% 94.92% 99.96% 97.26% 
50 99.94% 90.56% 99.96% 94.39% 
150 99.93% 82.97% 99.95% 87.71% 
≥40  30 99.95% 92.99% 99.97% 95.94% 
50 99.95% 89.38% 99.97% 93.52% 
150 99.91% 82.44% 99.94% 87.14% 
18.5-29.9  
20
00
 m
g 
II 
30 99.33% 96.62% 99.38% 98.18% 
50 98.68% 94.80% 98.75% 96.75% 
150 90.15% 75.28% 91.19% 80.01% 
30-39.9  
30 99.58% 96.75% 99.61% 98.33% 
50 99.04% 95.27% 99.10% 97.20% 
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150 94.19% 79.69% 94.76% 84.29% 
≥40  
30 99.75% 96.62% 99.77% 98.31% 
50 99.47% 95.46% 99.52% 97.45% 
150 96.38% 82.37% 96.72% 87.02% 
18.5-29.9  
20
00
 m
g 
PI
 
30 100.00% 97.52% 100.00% 98.99% 
50 100.00% 97.09% 100.00% 98.73% 
150 100.00% 90.09% 100.00% 94.14% 
30-39.9  
30 99.98% 97.31% 99.99% 98.85% 
50 99.98% 96.78% 99.99% 98.53% 
150 99.98% 89.30% 99.99% 93.57% 
≥40  30 89.30% 89.30% 100.00% 98.59% 
50 100.00% 96.31% 100.00% 98.20% 
150 100.00% 88.54% 100.00% 92.99% 
BMI = body mass index; CLCR = creatinine clearance; II = intermittent infusion; MIC = minimum inhibitory concentration; PI = prolonged 
infusion 
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This study analysed routine therapeutic drug monitoring (TDM) data from 17 obese (BMI ≥ 
30 kg/m2) and 17 non-obese (BMI <25 kg/m2) patients and found that meropenem CL 
was not significantly different between the critically ill obese and non-obese patients.59 
However, the total volume of distribution was non-significantly higher in obese group (40.0 
L Vs. 27.9 L; p = 0.10). The authors concluded that TDM should be performed routinely in 
obese critically ill patients. 
In a small prospective PK study of 9 morbidly obese critically ill patients (mean BMI 54.7 + 
8.6 kg/m2), Cheatham et al57 also found that CL of meropenem was similar between the 
enrolled morbidly obese patients and previously published data from non-obese patients. 
Like the present study and Hites et al59, total volume of distribution (in this study described 
as at steady state, Vss) was numerically larger in the morbidly obese group (37.8 L Vs. 
21.7 L). The authors suggested that standard dosing regimens of meropenem can 
provided adequate PK/PD target attainment for susceptible pathogens (MIC ≤2 mg/L). The 
data from these previous studies generally support our results, with BMI, often described 
as an obesity category, affecting Vd but not CL, and having little effect on achievement of 
PK/PD targets.  
This analysis has some limitations we would like to declare. First, estimation of CLCR using 
the Cockcroft-Gault method is known to be sub-optimal in critically ill patients. However, it 
is still commonly used clinically, although 8 or 24 h urinary CLCR measurements should be 
used where possible for increased accuracy.46,133,134 Given that we did not have urinary 
CLCR, we used Cockcroft-Gault CLCR in our modelling process and found that it greatly 
improved the model and so was retained. Notably, the weight descriptor for CG-CLCR was 
TBW and clinicians should use this weight metric when calculating CG-CLCR for 
meropenem dosing. Secondly, although this is the largest prospective PK study of its type 
for meropenem, the sample size in this study is not sufficient for quantifying the effect of 
meropenem exposure on patient outcome. Thirdly, in morbidly obese group (n = 6), the 
higher BMI was associated with predominantly a lower patients height rather than higher 
weight. It may be possible that a high BMI due to high weight affect the PK of meropenem 
in a different way. Furthermore, increasing the sample size may also have helped define 
additional patient factors associated with altered PK and include a wider range of height 
and weight, although these may not then be clinically relevant.   
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4.7 Conclusion 
In summary, this analysis presents the first population pharmacokinetic study of 
meropenem in critically ill patients with three different BMI categories. BMI appears to 
have a minimal effect on PK/PD target attainment in critically ill patients, while, increasing 
CG-CLCR (calculated using TBW) was strongly associated with a lower PK/PD target 
attainment. Higher doses or prolonged infusions should be applied for pathogens that have 
a higher MIC and/or in critically ill obese and non-obese patients with high CLCR. TDM of 
meropenem should be used where possible help optimise meropenem dosing regimens 
accordingly. 
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CHAPTER 5  
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Chapter 5. What is the effect of obesity on the population pharmacokinetics of 
piperacillin in critically ill patients? 
5.1 Synopsis 
The aim of this chapter is to prospectively describe the population pharmacokinetics of 
piperacillin in a cohort of critically ill patients including obese and morbidly obese patients. 
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5.2  “Published manuscript entitled “What is the effect of obesity on the 
population pharmacokinetics of piperacillin in critically ill patients?” 
The manuscript entitled “What is the effect of obesity on the population pharmacokinetics 
of piperacillin in critically ill patients?” has been submitted for publication (15th June, 2016). 
The co-authors contributed to the manuscript as follows: All literature review and analysis 
was performed by the PhD candidate, Abdulaziz S Alobaid, under the supervision of Prof 
Jason A Roberts. Dr. Steven C. Wallis, Miss Jenny Lisette Ordóñez Mejia, and the PhD 
candidate Abdulaziz S Alobaid were responsible for bioanalysis of piperacillin 
concentrations in plasma. Paul Jarrett, Therese Starr, Janine Stuart, Melissa Lassig-Smith 
assisted with obtaining ethical approval to conduct the study and patient consent and 
blood sampling. The PhD candidate, Abdulaziz S Alobaid, took the leading role in 
manuscript preparation and writing. The other co-authors contributed data to the analysis 
as well as critical review of the final version. 
The manuscript is presented as published; except figures and tables have been inserted 
into the text as slightly different positions and numbers. The numbering of pages, figures 
and tables have been re-arranged to fit overall style of the Thesis. The references are 
found alongside the other references of the Thesis, located in ‘Bibliography’.          
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Abstract 
Treating infections in critically ill obese and morbidly obese patients is challenging 
because of the combined physiological changes that result from obesity and critical illness. 
The aim of this study was to describe the population pharmacokinetics of piperacillin in a 
cohort of critically ill patients including obese and morbidly obese patients. Critically ill 
patients who received piperacillin/tazobactam were classified according to their body mass 
index (BMI) as non-obese; obese; and morbidly obese. Plasma samples were collected 
and piperacillin concentrations were determined by a validated chromatographic method. 
Population pharmacokinetic analysis and Monte Carlo dosing simulations was performed 
using Pmetrics®. Thirty-seven critically ill patients were enrolled (n=12 obese, n=12 
morbidly-obese). The patients’ mean ± SD age, weight and BMI were 50 ± 15 years, 104 ± 
35 kg and 38.0 ± 15.0 kg/m2, respectively. The concentration-time data were best 
described by a two compartment linear model. The mean ± SD parameter estimates for 
the final covariate model were clearance 14.0 ± 7.1 L/h, volume of distribution of the 
central compartment 49.0 ± 19.0 L, intercompartmental clearance from central to 
peripheral compartments 0.9 ± 0.6 L*h-1 and intercompartmental clearance from peripheral 
to central compartment 2.3  ± 2.8 L*h-1. Higher measured CLCR and shorter duration 
infusions were associated with a lower likelihood of achieving therapeutic piperacillin 
exposures in all BMI categories. Piperacillin pharmacokinetics is altered in the presence of 
obesity and critical illness. As with non-obese patients, prolonged infusions increase the 
likelihood of achieving therapeutic concentrations.   
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5.3 Introduction 
In recent decades, obesity has increased in prevalence globally 119,120. Similar to other 
western countries, in the USA, more than two-thirds of adults are either overweight or 
obese 121,122. Compared to non-obese, critically ill obese patients are thought to be at 
higher risk of mortality and morbidity from serious infections, including surgical site 
infections and community acquired pneumonia 11,123-125. Optimization of antimicrobial 
doses should be considered crucial in order to maximize success of treatment in these 
patients, although only sparse data are available to guide dosing 4,126. Indeed, obesity is 
thought to augment pathophysiological changes that occur due to critical illness, which 
may lead to additional changes in antimicrobial pharmacokinetics (PK) 23,108. The chronic 
physiological changes associated with obesity itself include reduced regional blood flow, 
increased cardiac output, and increased adipose tissues mass as well as increased lean 
mass, which may all affect antimicrobial PK/pharmacodynamics (PK/PD) 127.  
Piperacillin is a β-lactam antibiotic with a broad bactericidal activity against Gram-negative 
and Gram-positive aerobes and anaerobes 135. It is commonly co-formulated with 
tazobactam (β-lactamase inhibitor) to enhance its activity against most β-lactamase 
producing pathogen 136,137. Piperacillin exhibits time-dependent bacterial killing meaning 
that efficacy is determined by the duration that free concentrations are maintained above 
the minimum inhibitory concentration (fT>MIC) of pathogens 138. For piperacillin, fT>MIC ≥ 
50% of the dosing interval is considered necessary for maximal activity 139.  
There is little PK data of piperacillin in obese patients, particularly critically ill obese 
patients. Therefore, it remains unclear whether standard piperacillin dosing regimens will 
provide sufficient drug exposure. The aim of this prospective study was to describe the 
population PK of piperacillin in a cohort of critically ill non-obese, obese and morbidly 
obese patients. We then sought to perform Monte Carlo dosing simulations to identify 
optimised dosing regimens suitable for critically ill obese and morbidly obese patients. 
5.4 Methods 
5.4.1 Setting 
This was an observational PK study at a tertiary referral intensive care unit (ICU). Ethical 
approval was obtained from the local institutional Human Research Ethics Committee 
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(HREC/14/QRBW/88). Written informed consent was obtained from all participants or from 
their substitute decision-makers.   
5.4.2 Study population  
The inclusion criteria for this study were: (i) age ≥ 18 years; (ii) receiving piperacillin; and 
(iii) patient’s body mass index (BMI) ≥ 18.5 kg/m2. The exclusion criteria were: (i) patients 
on renal replacement therapy (RRT); (ii) pregnant women; (iii) patients with active 
bleeding; or (iv) patients with HIV or hepatitis. 
5.4.3 Study protocol 
Piperacillin was administered at the discretion of the treating clinician at dosage regimens 
of 4 g 6- or 8-hourly, as a 20 min infusion. Participants were categorised into three groups 
according to their BMI as follows: normal weight (BMI = 18.5-29.9 kg/m2); obese (BMI = 
30-39.9 kg/m2); and morbidly obese (BMI > 40 kg/m2). During one dosing interval, blood 
samples (≈3 ml) were taken from each participant to determine total plasma piperacillin 
concentrations at the following times, pre-dose, at 20 min (end of infusion), 40 min, 1, 3.5 
and 6 h after dose. Clinical and demographic data were collected on the day of sampling 
including age, sex, total body weight (TBW), ideal body weight (IBW), lean body weight 
(LBW) and BMI43. Clinical data also were recorded including Sequential Organ Failure 
Assessment (SOFA) 140 and Acute Physiology and Chronic Health Evaluation (APACHE) II 
scores 141, as well as serum albumin, serum creatinine concentrations and CLCR estimated 
by Cockcroft-Gault equation 115 (separately using TBW, LBW and IBW). Urine samples 
were also collected over the dosing interval to determined measured CLCR.  
5.4.4 Sample handling, storage and assay 
Blood samples were placed in an ice bath immediately and centrifuged at 3000 rpm for 10 
min. Plasma samples were stored at -80°C until bio-analysis. Piperacillin (0.5 – 500 mg/L) 
was measured in plasma by a validated UHPLC-MS/MS method on a Shimadzu Nexera2 
UHPLC system coupled to a Shimadzu 8030+ triple quadruple mass spectrometer 
(Shimadzu, Kyoto, Japan). Clinical samples were assayed alongside plasma calibrators 
Plasma (2.5 μL) was spiked with internal standard ([d5]-piperacillin) and treated with 
acetonitrile and centrifuged. The supernatant (0.5 μL) was injected to the UHPLC-MS/MS.  
The stationary phase was a C18 Shimadzu Shim-pack XR-ODS III, 1.6 μm column 
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(Shimadzu, Kyoto, Japan) operated at room temperature. The mobile phase A was 0.1% 
formic acid in water (v/v), and Mobile Phase B was 100% acetonitrile with 0.1% formic acid 
(v/v). The gradient went from 7.5% B to 95% B and back again for an 8.0 min run-time. 
The flow rate was 0.3 mL/min and produced a backpressure of about 5000 psi. Piperacillin 
was monitored by positive mode electrospray at MRM of 518.00→143.00. [d5]-piperacillin 
was monitored in positive mode at 523.00→148.00.  
The assay method was validated for linearity, matrix test, selectivity, LLOQ, recovery, 
reinjection stability and precision and accuracy using the FDA criteria for bioanalysis129. 
Precision was within 5.8% and accuracy was within 10.0% at the tested plasma QC 
piperacillin concentrations of 1.5, 50 and 400 mg/L.  
5.4.5 Population pharmacokinetic modelling 
One- and two-compartment models were developed using non-parametric adaptive grid 
algorithm within the Pmetrics package for R (Los Angeles, CA, USA) 130,131.  
We tested demographic and clinical characteristics for inclusion as covariates if they were 
biologically plausible for affecting piperacillin PK. The covariates assessed included age, 
sex, TBW, IBW, LBW, BMI, serum creatinine concentration, measured CLCR, CLCR 
estimated by Cockcroft-Gault equation (separately using TBW, LBW and IBW), albumin, 
SOFA, APACHE II. Covariates that significantly reduced the log-likelihood (p<0.05) and/or 
improved the goodness-of-fit plots were included in the model. 
5.4.6 Model diagnostics  
The goodness of fit of each model was evaluated by visual inspection of the observed-
predicted (population and individual) concentration scatter plots. The coefficient of 
determination of linear regression of observed-predicted values and the log-likelihood 
values from each run were also used to assess the goodness-of-fit. The predictive 
performance was evaluated using the mean prediction error (bias) and mean bias-adjusted 
squared prediction error (imprecision) of the population and individual predicted 
concentrations in the central compartment. The suitability of the final covariate model was 
assessed using a visual predictive check (VPC) after bootstrap resampling method (n = 
1000 simulations) and normalized prediction distribution errors 142.  
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5.4.7 Probability of target attainment (PTA)  
Monte Carlo simulations (n = 1000) were performed using Pmetrics software to determine 
the probability of target attainment (PTA) for 50% fT>MIC 139 for a variety of MICs for 
measured CLCR and BMI classes. Piperacillin dose of 4 g i.v. 4-, 6- and 8-hourly as 30-min 
intermittent infusion, 2- (4-hourly dosing), 3- (6-hourly dosing) or 4-h (8-hourly dosing) 
extended infusion, or continuous infusion (after 4 g loading dose over 30 min) were 
simulated at three different levels of renal function (measured CLCR = 30, 50 and 150 
mL/min) and three BMI classes of 20, 30 and 40 kg/m2. 
5.4.8 Fractional target attainment calculation (FTA)  
MIC data for Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae and 
Pseudomonas aeruginosa were used to determine the fractional target attainment  (FTA) 
according to MIC distributions from the European Committee for Antimicrobial 
Susceptibility and Testing (EUCAST) database143. The FTA compares the PK/PD 
exposure (PTA) against an MIC distribution to identify the achievement of target 
piperacillin exposure against the distribution of susceptibilities of the pathogen. A 
piperacillin dosing regimen was considered successful if the FTA value was ≥ 90%. 
Susceptible MIC distributions of these pathogens (MIC ≤ 8 mg/L, for A. baumannii, E. coli 
and K. pneumoniae and MIC ≤ 16 mg/L P. aeruginosa) were used to determine the FTA 
for directed therapy. Additionally, we used the entire MIC distribution (susceptible and 
resistant isolate values) to determine the FTA as would be encountered with empirical 
monotherapy.  
5.4.9 Statistical analysis 
Demographic data were analysed using the statistical software package IBM-SPSS 
statistics 22.0 (IBM, New York, USA). Continuous variables were defined as mean 
(standard deviation; SD). A P value <0.05 was considered statistically significant.  
5.5 Results 
5.5.1 Demographic and clinical data 
Thirty-seven critically ill patients (21 males) were enrolled in the study, 13 non-obese, 12 
obese and 12 morbidly-obese patients. In total 222 blood samples were obtained from the 
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participants. The demographics and clinical characteristics of the respective BMI 
categorisations are shown in Table 5-1. Only patients’ TBW, LBW, IBW and BMI were 
significantly different between the three BMI categorisations (P < 0.05).   
5.5.2 Pharmacokinetic model building 
Piperacillin PK was best described using a two-compartment linear model. The goodness 
of fit of the model was improved by inclusion of the following covariates, measured CLCR 
(normalised to 100 mL/min) for piperacillin clearance and by BMI (normalised to 35 kg/m2) 
for piperacillin Vc. When these covariates were added, each resulted in a significant 
decrease in the log likelihood. The final covariate model was statistically significantly better 
than the structural model (P <0.05). A scaling factor for obesity was also included for Vc 
and resulted in significant improvement to the model (P <0.001). The final covariate model 
was as follows:   
TVCL= CL*(CLCR/100) 
TVVC=Vc*((BMI/35)**0.75)*O 
Where TVCL is the typical value of piperacillin clearance, CL is the population parameter 
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Table 5-1. Demographic and clinical data  
 
All Patients  
(n = 37) 
Normal weight patients 
(n = 13) 
Obese patients 
(n = 12) 
Morbidly obese 
patients (n = 12) 
 
Variable Mean (SD) Mean (SD) Mean (SD) Mean (SD) P Value 
      
Age (Year) 50 (15) 48 (17) 47 (12) 54 (16) 0.46 
Weight (kg) 104 (35)  81 (11) 90 (10) 143 (34) <0.00 
Ideal body weight (kg) 61 (13) 68 (9) 60 (11) 55 (16) 0.029 
Lean body weight (kg)  52 (23) 60 (6) 58 (10) 38 (10) 0.30 
Height (cm) 167 (12) 173 (9) 167 (10) 161 (15) 0.46 
Male sex* 21 (57) 11 (84) 6 (50) 4(33) - 
BMI (kg/m2) 38 (15) 27 (3) 33 (2) 55(14) <0.00 
Serum creatinine  
(µmol/L) 
95 (53) 87 (31) 76 (28) 124 (78) 
0.66 
Measured CLCR 
(mL/min) 
108 (59) 123 (59) 113 (45) 86 (68) 
0.26 
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CG-TBW (mL/min) 165 (86) 135 (68) 173 (60) 191 (116) 0.25 
CG-IBW (mL/min) 103 (58) 117 (66) 114 (40) 77 (58) 0.16 
CG-LBW (mL/min) 90(57) 102 (54) 108 (34) 58 (68) 0.06 
SOFA score 6 (3) 7 (3) 7 (4) 4 (4) 0.07 
APACHE II score 21 (7) 21 (7) 21 (7) 21 (7) 0.97 
APACHE II = Acute Physiology and Chronic Health Evaluation; BMI = body mass index; ClCR = measured creatinine clearance; CG-TBW 
= estimated CLCR using Cockcroft-Gault equation based on total body weight; CG-IBW = estimated CLCR using Cockcroft-Gault equation 
based on ideal body weight; CG-LBW = estimated CLCR using Cockcroft-Gault equation based on lean body weight; SOFA = Sequential 
Organ failure Assessment.  
*Data of male’s gender is presented as number (%). 
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estimate of piperacillin clearance, CLCR is the measured creatinine clearance, TVVc is the 
typical value of piperacillin distribution in the central compartment, Vc is the population 
parameter estimate of piperacillin volume of distribution of the central compartment, BMI is 
body mass index, O is a scaling factor for obesity.     
The mean ± SD population PK parameter estimates from the final covariate model are 
shown in Table 5-2. The diagnostic plots confirmed the appropriateness of the model as 
shown in Figure 5-1-a, 5-1-b, 5-1-c. The effect of BMI on piperacillin clearance and central 
volume of distribution is shown in Figures 8 and 9. The final covariate model was then 
used for Monte Carlo dosing simulations.  
 
Table 5-2. Parameter estimates for piperacillin from the final covariate two-compartment 
population pharmacokinetic model. 
 Mean (SD) Coefficient of variation (%) Median 
CL (L/h) 14.0 (7.1) 51.38 10.72 
Vc (L) 49.0 (19.0) 37.68 57.97 
KCP (h-1) 0.9 (0. 6) 68.02 0.80 
KPC (h-1) 2.3 (2.8) 120.360 1.36 
O 0.4 (0.2) 43.87 0.27 
CL = population clearance of piperacillin ; Vc = population volume of distribution of central 
compartment; kcp = rate constant for piperacillin distribution from the central to peripheral 
compartment; kpc = rate constant for piperacillin distribution from the peripheral to central 
compartment, O = scaling factor for obesity. 
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Figure 5-1. Diagnostic plots for the final population pharmacokinetic covariate model 
(piperacillin).  
(a) Observed piperacillin concentrations versus population predicted piperacillin 
concentration (R2 =0.653). (b) Observed piperacillin concentrations versus individual 
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predicted piperacillin concentration (R2 =0.976). (c) Visual predictive check of piperacillin 
plasma data.  
5.5.3 Dosing simulations 
Monte Carlo simulations and PTA for achieving 50% fT>MIC for a 4g piperacillin dose at 
various BMI, measured CLCR and different dosing regimens are presented in Table 5-3. 
The results showed that a higher measured CLCR was associated with a lower PTA for 
different BMI classes. At lower and moderate measured CLCR (30 and 50 mL/min), the 
intermittent dosing regimens of piperacillin 4g 4- and 6- hourly showed similar PTA for 
non-obese, obese and morbidly obese patients. In contrast, piperacillin doses of 4g 8-
hourly had variable PTA at low to moderate measured CLCR between BMI classes. 
Moreover, the intermittent dosing regimens of piperacillin 4g 4-hourly at BMIs of 30 and 40 
kg/m2 showed higher PTA (MIC ≤ 8mg/L) compared to that achieved at a BMI of 20 kg/m2 
(MIC ≤ 4m/L). All extended and continuous infusion dosing regimens of piperacillin 
achieved PK/PD targets up to a MIC of at least 8 mg/L.  
5.5.4 Fractional target attainment   
The FTA for different simulated piperacillin dosing regimens and patient BMIs and 
measured CLCR for both directed and empirical coverage of A. baumannii, E. coli, K. 
pneumonia and P. aeruginosa are shown in Table 5-4. For A. baumannii, empirical 
therapy, all piperacillin dosing regimens failed to achieve the 90% target in all patients 
groups, including in scenarios of CLCR at 30 mL/min. Only the intermittent piperacillin 
dosing of 6- and 8-hourly failed to achieve the 90% target for A. baumannii directed 
therapy in patients with a BMI of 20 and 30 kg/m2 at a higher CLCR (150mL/min). 
Piperacillin prolonged infusions as directed therapy achieve the 90% target for E.coli, K. 
pneumoniae and P. aeruginosa in all groups of patients. Moreover, almost all piperacillin 
dosing regimens failed to achieve the 90% target for P. aeruginosa in all groups of 
patients, particularly, in patients with CLCR ≥ 50 mL/min.  
 
The effect of the BMI, described in terms of non-obese, obese and morbidly obese, on 
piperacillin CL and Vc is described in Figures 5-2 and 5-3, respectively. 
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Table 5-3. Piperacillin 4000 mg probability of target attainment (free drug concentrations remain above the MIC for 50% of the dosage 
interval) for various BMI, measured CLCR, and dosing intervals and method of administrations. 
Piperacillin 4000 mg 4-hourly MIC (mg/L) 
BMI (kg/m2) Dose CLCR (mL/min) 0.25 0.5 1 2 4 8 16 32 64 
20 
40
00
 m
g 
in
te
rm
itt
en
t 4
-h
ou
rly
  
30 + + + + + + + + + 
50 + + + + + + + + - 
150 + + + + + - - - - 
30 
30 + + + + + + + + + 
50 + + + + + + + + - 
150 + + + + + + - - - 
40 
30 + + + + + + + + + 
50 + + + + + + + + - 
150 + + + + + + - - - 
20 
40
00
 m
g 
ex
te
nd
ed
 
in
fu
si
on
 4
-h
ou
rly
 30 + + + + + + + + + 
50 + + + + + + + + - 
150 + + + + + + + - - 
30 30 + + + + + + + + + 
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50 + + + + + + + + - 
150 + + + + + + + - - 
40 
30 + + + + + + + + + 
50 + + + + + + + + - 
150 + + + + + + + - - 
20 
40
00
 m
g 
co
nt
in
uo
us
 in
fu
si
on
 4
-h
ou
rly
 
30 + + + + + + + + + 
50 + + + + + + + + - 
150 + + + + + + + - - 
30 
30 + + + + + + + + + 
50 + + + + + + + + - 
150 + + + + + + + - - 
40 
30 + + + + + + + + + 
50 + + + + + + + + - 
150 + + + + + + + - - 
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Piperacillin 4000 mg 6-hourly MIC (mg/L) 
BMI (kg/m2) Dose CLCR (mL/min) 0.25 0.5 1 2 4 8 16 32 64 
20 
40
00
 m
g 
in
te
rm
itt
en
t 6
-h
ou
rly
 
30 + + + + + + + + - 
50 + + + + + + + - - 
150 + + + - - - - - - 
30 
30 + + + + + + + + - 
50 + + + + + + + - - 
150 + + + + - - - - - 
40 
30 + + + + + + + + - 
50 + + + + + + + - - 
150 + + + + + - - - - 
20 
40
00
 m
g 
ex
te
nd
ed
 in
fu
si
on
 
6-
ho
ur
ly
 
30 + + + + + + + + - 
50 + + + + + + + + - 
150 + + + + + + - - - 
30 
30 + + + + + + + + - 
50 + + + + + + + + - 
150 + + + + + + - - - 
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40 
30 + + + + + + + + - 
50 + + + + + + + + - 
150 + + + + + + - - - 
20 
40
00
 m
g 
co
nt
in
uo
us
 in
fu
si
on
 6
-h
ou
rly
 
30 + + + + + + + + + 
50 + + + + + + + + - 
150 + + + + + + - - - 
30 
30 + + + + + + + + + 
50 + + + + + + + + - 
150 + + + + + + - - - 
40 
30 + + + + + + + + + 
50 + + + + + + + + - 
150 + + + + + + - - - 
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Piperacillin 4000 mg 8-hourly MIC (mg/L) 
BMI (kg/m2) Dose CLCR (mL/min) 0.25 0.5 1 2 4 8 16 32 64 
20 
40
00
 m
g 
in
te
rm
itt
en
t 8
-h
ou
rly
 
30 + + + + + + + - - 
50 + + + + + + - - - 
150 - - - - - - - - - 
30 
30 + + + + + + + + - 
50 + + + + + + - - - 
150 + - - - - - - - - 
40 
30 + + + + + + + + - 
50 + + + + + + + - - 
150 + + - - - - - - - 
20 
40
00
 m
g 
ex
te
nd
ed
 
in
fu
si
on
 8
-h
ou
rly
 
30 + + + + + + + + - 
50 + + + + + + + - - 
150 + + + + + + - - - 
30 
30 + + + + + + + + - 
50 + + + + + + + - - 
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150 + + + + + + - - - 
40 
30 + + + + + + + + - 
50 + + + + + + + - - 
150 + + + + + + - - - 
20 
40
00
 m
g 
co
nt
in
uo
us
 in
fu
si
on
 8
-h
ou
rly
 
30 + + + + + + + + - 
50 + + + + + + + - - 
150 + + + + + + - - - 
30 
30 + + + + + + + + - 
50 + + + + + + + - - 
150 + + + + + + - - - 
40 
30 + + + + + + + + - 
50 + + + + + + + - - 
150 + + + + + + - - - 
 
(+) at least 90% of simulations achieve PK/PD target; (-) < 90% of simulations achieved PK/PD target; BMI= body mass index; CLCR = 
measured creatinine clearance; MIC = minimum inhibitory concentration.  
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Table 5-4. Piperacillin 4 g fractional target attainment for various BMI, measured CLCR, and dosing intervals and methods of 
administration for Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa. 
 Pathogens  
A. baumannii E. coli K. pneumoniae P. aeruginosa 
BMI 
(kg/m2) 
Dose  CLCR 
(mL/min) 
MIC for 
Directed 
therapy 
MIC for 
Empirical 
therapy 
MIC for 
Directed 
therapy 
MIC for 
Empirical 
therapy 
MIC for 
Directed 
therapy 
MIC for 
Empirical 
therapy 
MIC for 
Directed 
therapy 
MIC for 
Empirical 
therapy 
20 
40
00
 m
g 
in
te
rm
itt
en
t 4
-h
ou
rly
 
30 100.00% 68.76% 100.00% 98.94% 100.00% 95.26% 99.99% 93.08% 
50 99.96% 55.60% 99.98% 98.02% 99.96% 92.04% 99.92% 87.18% 
150 94.14% 32.97% 97.33% 92.25% 95.41% 81.75% 84.95% 66.11% 
30 
30 100.00% 67.86% 100.00% 98.91% 100.00% 95.09% 100.00% 92.82% 
50 99.98% 55.97% 100.00% 98.08% 99.99% 92.12% 99.96% 87.40% 
150 97.41% 35.45% 98.92% 94.16% 98.06% 84.75% 91.33% 71.35% 
40 30 100.00% 70.50% 100.00% 98.84% 100.00% 94.81% 100.00% 92.35% 
50 100.00% 55.84% 100.00% 98.08% 100.00% 92.07% 99.99% 87.35% 
150 100.00% 41.48% 99.58% 95.05% 99.11% 86.16% 94.22% 73.75% 
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20 
40
00
 m
g 
ex
te
nd
ed
 in
fu
si
on
 4
-h
ou
rly
 
30 100.00%  69.89% 100.00% 99.02% 100.00% 95.56% 100.00% 93.63% 
50 100.00% 57.80% 100.00% 98.24% 100.00% 92.55% 100.00% 88.32% 
150 100.00% 41.46% 100.00% 96.47% 100.00% 88.78% 99.94% 79.73% 
30 
30 100.00% 67.72% 100.00% 98.90% 100.00% 95.05% 100.00% 92.76% 
50 100.00% 57.02% 100.00% 98.18% 100.00% 92.36% 100.00% 87.94% 
150 100.00% 40.25% 100.00% 96.27% 100.00% 88.45% 99.78% 78.90% 
40 30 100.00% 67.06% 100.00% 98.87% 100.00% 94.93% 100.00% 92.57% 
50 100.00% 56.53% 100.00% 98.14% 100.00% 92.24% 100.00% 87.70% 
150 100.00% 40.82% 100.00% 96.37% 100.00% 88.62% 99.88% 79.31% 
20 
40
00
 m
g 
co
nt
in
uo
us
 in
fu
si
on
 4
-h
ou
rly
 
30 100.00% 73.07% 100.00% 99.17% 100.00% 96.22% 100.00% 94.70% 
50 100.00% 59.57% 100.00% 98.36% 100.00% 92.96% 100.00% 89.09% 
150 100.00% 41.53% 100.00% 96.47% 100.00% 88.77% 99.84% 79.70% 
30 30 100.00% 71.72% 100.00% 99.12% 100.00% 96.00% 100.00% 94.34% 
50 100.00% 59.14% 100.00% 98.33% 100.00% 92.84% 100.00% 88.89% 
150 100.00% 41.51% 100.00% 96.46% 100.00% 88.76% 99.84% 79.68% 
40 30 100.00% 70.50% 100.00% 99.06% 100.00% 95.74% 100.00% 93.90% 
50 100.00% 58.63% 100.00% 98.30% 100.00% 92.70% 100.00% 88.65% 
150 100.00% 41.48% 100.00% 96.46% 100.00% 88.76% 99.84% 79.67% 
 
  
104 
 Pathogens  
A. baumannii E. coli K. pneumoniae P. aeruginosa 
BMI 
(kg/m2) 
Dose  CLCR 
(mL/min) 
MIC for 
Directed 
therapy 
MIC for 
Empirical 
therapy 
MIC for 
Directed 
therapy 
MIC for 
Empirical 
therapy 
MIC for 
Directed 
therapy 
MIC for 
Empirical 
therapy 
MIC for 
Directed 
therapy 
MIC for 
Empirical 
therapy 
20 
40
00
 m
g 
in
te
rm
itt
en
t 6
-h
ou
rly
 
30 99.98% 57.38% 100.00% 98.18% 99.99% 92.48% 99.95% 88.07% 
50 99.78% 46.83% 99.81% 96.92% 99.73% 89.70% 99.15% 82.22% 
150 79.81% 25.04% 84.98% 79.73% 78.24% 65.64% 58.69% 45.08% 
30 
30 100.00% 57.01% 100.00% 98.17% 100.00% 92.37% 100.00% 87.92% 
50 99.93% 47.85% 99.97% 97.25% 99.93% 90.15% 99.69% 83.13% 
150 86.99% 28.15% 92.93% 87.45% 88.61% 74.81% 72.14% 55.51% 
40 30 100.00% 56.33% 100.00% 98.11% 100.00% 92.18% 100.00% 87.58% 
50 99.95% 47.93% 99.99% 97.31% 99.98% 90.23% 99.86% 83.31% 
150 91.32% 29.91% 96.11% 90.57% 93.15% 78.85% 78.96% 60.80% 
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20 
40
00
 m
g 
ex
te
nd
ed
 in
fu
si
on
 6
-h
ou
rly
 
30 100.00% 58.67% 100.00% 98.30% 100.00% 92.75% 100.00% 88.71% 
50 100.00% 58.67% 100.00% 98.23% 100.00% 92.75% 100.00% 88.71% 
150 99.98% 36.64% 100.00% 98.14% 99.99% 87.06% 97.37% 75.50% 
30 
30 100.00% 57.72% 100.00% 98.30% 100.00% 92.52% 100.00% 88.25% 
50 100.00% 49.56% 100.00% 97.53% 100.00% 90.65% 100.00% 84.29% 
150 99.98% 36.33% 100.00% 97.47% 99.99% 86.91% 97.01% 75.13% 
40 30 100.00% 56.51% 100.00% 95.50% 100.00% 92.20% 100.00% 87.66% 
50 100.00% 49.00% 100.00% 95.42% 100.00% 90.52% 100.00% 84.01% 
150 99.98% 36.17% 100.00% 95.37% 99.99% 86.81% 96.72% 74.89% 
20 
40
00
 m
g 
co
nt
in
uo
us
 in
fu
si
on
 6
-h
ou
rly
 
30 100.00% 61.85% 100.00% 98.53% 100.00% 93.58% 100.00% 90.21% 
50 100.00% 51.71% 100.00% 97.72% 100.00% 91.15% 100.00% 85.36% 
150 100.00% 36.24% 100.00% 95.38% 100.00% 86.83% 96.70% 74.93% 
30 30 100.00% 60.93% 100.00% 98.47% 100.00% 93.34% 100.00% 89.79% 
50 100.00% 51.47% 100.00% 97.70% 100.00% 91.08% 100.00% 85.24% 
150 100.00% 36.24% 100.00% 95.38% 100.00% 86.83% 96.72% 74.93% 
40 30 100.00% 59.92% 100.00% 98.40% 100.00% 93.07% 100.00% 89.30% 
50 100.00% 51.14% 100.00% 97.68% 100.00% 90.99% 100.00% 85.07% 
150 100.00% 36.24% 100.00% 95.38% 100.00% 86.83% 96.70% 74.93% 
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 Pathogens  
A. baumannii E. coli K. pneumoniae P. aeruginosa 
BMI 
(kg/m2) 
Dose  CLCR 
(mL/min) 
MIC for 
Directed 
therapy 
MIC for 
Empirical 
therapy 
MIC for 
Directed 
therapy 
MIC for 
Empirical 
therapy 
MIC for 
Directed 
therapy 
MIC for 
Empirical 
therapy 
MIC for 
Directed 
therapy 
MIC for 
Empirical 
therapy 
20 
40
00
 m
g 
in
te
rm
itt
en
t 8
-h
ou
rly
 
30 99.89% 49.53% 99.97% 97.40% 99.93% 90.54% 99.62% 83.93% 
50 97.68% 38.64% 98.67% 94.59% 97.98% 85.88% 93.74% 74.45% 
150 56.54% 16.86% 49.48% 46.23% 40.36% 33.54% 24.71% 18.86% 
30 
30 100.00% 50.09% 100.00% 97.52% 100.00% 90.74% 99.93% 84.43% 
50 99.15% 40.78% 99.63% 95.88% 99.35% 87.74% 97.16% 77.74% 
150 66.85% 20.14% 67.31% 62.94% 57.52% 47.91% 37.78% 28.85% 
40 30 100.00% 50.01% 100.00% 97.54% 100.00% 90.72% 99.97% 84.44% 
50 99.65% 41.82% 99.91% 96.34% 99.78% 88.45% 98.39% 79.05% 
150 73.43% 22.36% 78.50% 73.47% 69.42% 57.94% 47.90% 36.60% 
  
  
107 
20 
40
00
 m
g 
ex
te
nd
ed
 in
fu
si
on
 6
-h
ou
rly
 
30 100.00% 53.51% 100.00% 97.89% 100.00% 91.52% 100.00% 86.23% 
50 100.00% 45.99% 100.00% 97.12% 100.00% 89.85% 100.00% 82.39% 
150 99.18% 32.95% 200.64% 94.36% 99.69% 84.85% 91.34% 70.16% 
30 
30 100.00% 52.23% 100.00% 97.77% 100.00% 91.21% 100.00% 85.59% 
50 100.00% 45.55% 100.00% 97.06% 100.00% 89.75% 100.00% 82.15% 
150 99.25% 33.08% 99.88% 94.41% 99.72% 84.94% 91.62% 70.38% 
40 30 100.00% 51.31% 100.00% 97.69% 100.00% 91.01% 100.00% 85.14% 
50 100.00% 45.07% 100.00% 97.00% 100.00% 89.64% 99.99% 81.88% 
150 99.33% 33.10% 99.89% 94.42% 99.74% 84.97% 91.72% 70.45% 
20 
40
00
 m
g 
co
nt
in
uo
us
 in
fu
si
on
 6
-h
ou
rly
 
30 100.00% 55.84% 100.00% 98.07% 100.00% 92.11% 100.00% 87.38% 
50 100.00% 47.21% 100.00% 97.25% 100.00% 90.14% 100.00% 83.04% 
150 99.73% 33.32% 99.96% 94.52% 99.90% 85.18% 92.34% 70.92% 
30 30 100.00% 55.39% 100.00% 98.04% 100.00% 91.99% 100.00% 87.15% 
50 100.00% 47.15% 100.00% 97.25% 100.00% 90.12% 100.00% 83.01% 
150 99.73% 33.32% 99.96% 94.52% 99.90% 85.18% 92.34% 70.92% 
40 30 100.00% 54.73% 100.00% 97.99% 100.00% 91.81% 100.00% 86.82% 
50 100.00% 47.05% 100.00% 97.24% 100.00% 90.09% 100.00% 82.96% 
150 99.73% 33.31% 99.96% 94.52% 99.90% 85.17% 92.32% 70.91% 
BMI = body mass index; CLCR = measured creatinine clearance; MIC = minimum inhibitory concentration. 
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Figure 5-2. Piperacillin clearance Vs. BMI class. 
 
 
Figure 5-3. Piperacillin central volume of distribution Vs. BMI class. 
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5.6 Discussion  
5.6.1 Key findings 
This is the first population PK study of piperacillin targeted at critically ill non-obese, obese 
and morbidly obese patients. We found that BMI and CLCR all significantly affected 
piperacillin PK. Furthermore, as expected, we found that more frequent intermittent 
piperacillin doses produced a higher PTA across all BMI categories. We also found that 
piperacillin extended and continuous infusion greatly improved PTA (MIC up to at least 8 
mg/L) in the presence of different BMIs and measured CLCR. These data support others 
60,144,145, which suggest that extended and continuous infusions can normalise any effects 
of altered weight and renal function on achievement of therapeutic concentrations. 
5.6.2 Relationship with previous papers 
Piperacillin PK in critically ill non-obese patients appears to be different from healthy 
subjects 146. This is likely due to the pathophysiological alterations that occur in critically ill 
patients, such as organ dysfunction, including renal and hepatic, as well as fluid shifts and 
capillary permeability changes that can alter piperacillin clearance and volume of 
distribution 23,97. The presence of obesity may exaggerate these effects. However, to date, 
there is a shortage of PK studies of piperacillin in obese critically ill patients. Hites et al. 59 
found both the piperacillin volume of distribution as well as clearance were not significantly 
different between obese and non-obese critically ill patients. However, the authors 
suggested that therapeutic drug monitoring (TDM) should still be used for critically ill 
patients, including obese, as critical illness itself is responsible for largely unpredictable PK 
alterations.   
In contrast, Sturm et al.61 examined piperacillin in 9 morbidly obese critically ill patients and 
found that a higher volume of distribution and lower clearance of piperacillin (31.0 L Vs. 
22.4 L and 6.0 L/h Vs. 13.7 L/h, respectively) compared to that reported for non-obese 
patients. At a piperacillin dose of 4g 6-hourly administered over 30 minutes, all patients in 
the study achieved the PK/PD target of 50% fT>MIC using a higher MIC target (16 mg/L). 
The authors suggested that piperacillin administered as a 4-h extended infusion appears 
to have little advantage over a short 30 minute infusion. This conclusion conflicts our 
findings that showed piperacillin extended and continuous infusions increased PK/PD 
  
110 
target achievement compared to intermittent regimens, particularly in patients with higher 
CLCR.  
A large retrospective study of 1400 patients by Alobaid et al. 83 examined the impact of 
obesity on the unbound plasma concentrations of piperacillin and meropenem. This study 
showed that obesity was associated with significantly lower unbound piperacillin 
concentrations (29.4 mg/L) compared to non-obese patients (42.0 mg/L). Similarly, in the 
present study, we found that piperacillin clearance was higher in the morbidly obese 
(19.7±8.6 L/hr) group compared to both the obese (11.1±3.0 L/hr) and non-obese groups 
(10.7±5.0 L/hr) as shown in Figure 5-2. We also found that increasing BMI was 
significantly associated with increasing Vc highlighting the effect of increasing obesity on 
likely changes in piperacillin exposure Figure 5-3. This result is likely due to consequent 
prolongation of drug half-life associated with an increase in Vc leading to more sustained 
concentrations exceeding the therapeutic concentration target.       
A study by Roberts et al. 146 investigated the PK of piperacillin administered by either 
continuous or intermittent dosing in critically ill patients with sepsis, including obese 
patients. The authors found that both piperacillin volume of distribution (25.0 L Vs. 10.4 L) 
and clearance (17.2 L/h Vs. 11.3 L/hr) were higher compared to healthy adults 147. The 
authors used a simulation approach to show that an increased length of infusion could 
increase achievement of therapeutic concentrations in the presence of the 
pathophysiological changes associated with critical illness.  Furthermore, in obese non-
critically ill patients, Cheatham et al. 62 found that piperacillin volume of distribution 33.4 L 
Vs. 21.8 L) and clearance (13. 7 L/h Vs. 8.6 L/h) were numerically higher compared to 
non-obese non-critically ill patients. The authors suggested that a higher piperacillin dose 
was necessary to ensure achievement of therapeutic concentrations.  
5.6.3 Implications of study findings 
Our results suggest that different piperacillin dosing regimens should be used to increase 
PK/PD target attainment in critically ill patients dependent on their renal function and BMI. 
A 4 g piperacillin intermittent dose (6- and 8-hourly) for obese/non-obese critically ill 
patients with low to moderate measured CLCR appears appropriate for targeting pathogens 
with a MIC ≤ 8 mg/L, such as E. coli. However, in patients with higher measured CLCR or 
when pathogens with a higher MIC (≥16 mg/L), such as P. aeruginosa are suspected, the 
piperacillin dose is best given more frequently (4-hourly) to achieve PK/PD targets.  
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Furthermore, less frequent prolonged piperacillin infusions could also be considered when 
targeting pathogens with a MIC ~8 mg/L in obese/ non-obese critically ill patients including 
those patients with a higher measured CLCR. Prolonged piperacillin infusion (e.g. 4 g 6-
hourly as a 3-h infusion) are recommended for targeting pathogens with a MIC ~ 16mg/L 
for patients with a higher measured CLCR (150 mL/min). However, knowledge of patient 
renal function is important and should be used for more accurate dose individualisation. 
When considering piperacillin for empirical therapy, all dosing regimens failed to achieve 
the 90% target for both A. baumannii and P. aeruginosa. In such cases it would appear 
that combination therapy would be appropriate to ensure maximal therapy.  
5.6.4 Study limitations  
Although this study is the first population PK of piperacillin in critically ill non-obese, obese 
and morbidly obese patients, it has some limitations that should be declared. First, despite 
the drug formulation containing both piperacillin (β-lactam antibiotic) and tazobactam (β-
lactamase inhibitor), we did not measure tazobactam concentrations. Secondly, despite, 
this being considered a relatively large PK study in critically ill patients, the sample size 
would not be considered sufficient for quantifying the effect of piperacillin exposure on 
patient outcome. Finally, we only collected blood samples which may not necessarily 
indicate concentrations at the site of infection and more specific mechanistic studies would 
be required to determine penetration into the interstitial fluid of different tissues of obese 
and morbidly obese patients. 
5.7 Conclusion 
In summary, this study presents the first population PK study of piperacillin in critically ill 
patients in three different BMI categories. Although increasing BMI does not appear to 
have a large effect on PK/PD target attainment in critically ill patients, an increasing 
measured CLCR was strongly associated with a lower PK/PD target attainment. A 
piperacillin dose of 4g 4-, 6- or 8- hourly as prolonged infusion regimens are required to 
achieve the PK/PD targets. Also, more frequent intermittent or higher intermittent doses 
provide another option for less susceptible pathogens, including P. aeruginosa and/or in 
critically ill obese and non-obese patients with high CLCR. TDM of piperacillin should be 
used where available for dose optimization. 
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Chapter 6. What is the effect of obesity on the population pharmacokinetics of 
fluconazole in critically ill patients? 
6.1 Synopsis 
The aim of this chapter is to prospectively describe the population PK of fluconazole in a 
cohort of critically ill patients including obese and morbidly obese patients. 
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6.2 “Published manuscript entitled “What is the effect of obesity on the population 
pharmacokinetics of fluconazole in critically ill patients?” 
The manuscript entitled “What is the effect of obesity on the population pharmacokinetics 
of fluconazole in critically ill patients?” has been submitted for publication (18th May 2016).   
The co-authors contributed to the manuscript as follows: All literature review and analysis 
was performed by the PhD candidate, Abdulaziz S Alobaid, under the supervision of Prof 
Jason A Roberts. Dr. Steven C. Wallis, Miss Jenny Lisette Ordóñez Mejia, and the PhD 
candidate Abdulaziz S Alobaid were responsible for bioanalysis of fluconazole 
concentrations in plasma. Paul Jarrett, Therese Starr, Janine Stuart, Melissa Lassig-Smith 
assisted with obtaining ethical approval to conduct the study and patient consent and 
blood sampling. The PhD candidate, Abdulaziz S Alobaid, took the leading role in 
manuscript preparation and writing. The other co-authors contributed data to the analysis 
as well as critical review of the final version. 
The manuscript is presented as published; except figures and tables have been inserted 
into the text as slightly different positions and numbers. The numbering of pages, figures 
and tables have been re-arranged to fit overall style of the Thesis. The references are 
found alongside the other references of the Thesis, located in ‘Bibliography’.          
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Abstract 
Critical illness can lead to severe pathophysiological changes, which dramatically alter 
antimicrobial pharmacokinetics. Obesity may augment these changes. The aim of this 
study is to describe the population pharmacokinetics of fluconazole in a cohort of critically 
ill non-obese, obese and morbidly obese patients. Critically ill patients prescribed 
fluconazole were recruited into three body mass index (BMI) cohorts, non-obese (18.5-
29.9 kg/m2); obese (30.0-39.9 kg/m2); and morbidly obese (≥ 40 kg/m2). Serial plasma 
samples were taken and fluconazole concentrations were determined using a validated 
chromatographic method. Population pharmacokinetic analysis and Monte Carlo dosing 
simulations were undertaken with Pmetrics®. Twenty-one critically ill patients (11 male) 
were enrolled in the study including obese (n = 6) and morbidly obese (n= 4). The patient’s 
mean ± SD age, weight and BMI were 54 ± 15 years, 90 ± 24 kg and 31 ± 9 kg/m2, 
respectively. A two- compartment linear model described the data adequately. The mean ± 
SD population pharmacokinetic parameter estimates were clearance (CL) 0.95 ± 0.48 L/h, 
volume of distribution of the central compartment (Vc) 15.10 ± 11.78 L, intercompartmental 
clearance from central to peripheral compartment   5.41 ± 2.28 L/h and intercompartmental 
clearance from peripheral to central compartment 2.92 ± 4.95 L/h. A fluconazole dose of 
200 mg daily was insufficient to achieve the pharmacodynamic target (fAUC/MIC 100) for 
pathogens with higher MICs (>2 mg/L) in critically ill patients including patients with BMI 
greater than 30 kg/m2. A fluconazole loading dose of 12 mg/kg and maintenance dose of 6 
mg/kg/day are achieved pharmacodynamic targets for higher MICs. A weight-based 
loading dose of 12 mg/kg followed by a daily maintenance dose of 6 mg/kg, according to 
renal function, is required in critically ill patients for pathogens with a MIC ≥ 2 mg/L.  
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6.3 Introduction 
Recent decades has seen an increased prevalence in obesity worldwide 119,120. More than 
two-thirds of adults in the US are either overweight or obese, whilst one-third are obese 
121,122. Mortality and morbidity are higher in obese patients compared to non-obese 
patients for different types of infections, such as surgical site infections, community 
acquired pneumonia, and peritonitis in peritoneal dialysis patients 11,123-125. Optimization of 
dosing is essential to minimize the risk of therapeutic failure in these patients. However, 
only few data are available to guide clinicians for effective antimicrobial dosing in obese 
patients. 
Moreover, dosing in obese critically ill patients is relatively unexplored and is thus a highly 
challenging scenario for clinicians 4,126. Although, only sparse data are available, it is 
possible that the altered pharmacokinetics (PK) that occurs in critically ill patients are 
heightened by presence of obesity due to concurrent pathophysiological changes 23,108. 
The physiological changes that are likely to occur in obese compared to non-obese 
patients include reduced regional blood flow, increased cardiac output, and increased fat 
and lean mass 127. These changes in obese patients are likely to alter the 
PK/pharmacodynamics (PK/PD) of antimicrobials thereby requiring dosing adjustments to 
ensure optimal patient outcomes. As the prevalence of critically ill obese patients 
increases, clinicians will face an increasing challenge to ensure effective antimicrobial 
therapy. 
Fluconazole is a commonly used triazole antifungal in critically ill patients 9. It is commonly 
prescribed to treat infections caused by Candida albicans and Candida tropicalis 9. In 
healthy individuals and non-critically ill patients, fluconazole has a favourable PK and 
safety profile, and exhibits a long half-life (30 h) enabling once-daily dosing 148. 
Fluconazole is excreted unchanged in urine with, ≈ 80% renal clearance. It has low plasma 
protein binding (11-12%) and a moderate volume of distribution (Vd), about 0.65-0.70 L/kg 
148.    
In critically ill non-obese patients, fluconazole PK appears to be different from healthy 
subjects 149. This is likely due to the organ dysfunction, renal and/ or hepatic, as well as 
fluid shifts and capillary permeability changes that can alter fluconazole clearance and Vd.  
There is little or no data about the PK of fluconazole in obese patients, particularly critically 
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ill obese patients. Therefore, it remains unclear whether standard fluconazole dosing 
regimens will provide sufficient drug exposure.  
The aim of this prospective study was to describe the population PK of fluconazole in a 
cohort of critically ill non-obese, obese and morbidly obese patients.  
6.4 Methods 
6.4.1 Setting 
This was an observational PK study at a tertiary referral intensive care unit (ICU). Ethical 
approval was obtained from the local institutional Human Research Ethics Committee 
(HREC/14/QRBW/88). Written informed consent was obtained from all participants or from 
their substitute decision-makers.   
6.4.2 Study population  
The inclusion criteria for this study were: (i) age ≥ 18 years; (ii) receiving fluconazole 
(prophylaxis or treatment); and (iii) patient’s body mass index (BMI) ≥ 18.5 kg/m2. The 
exclusion criteria were: (i) patients on renal replacement therapy (RRT); (ii) pregnant 
women; (iii) patients with active bleeding; or (iv) patients with HIV or hepatitis. 
6.4.3 Study protocol 
Fluconazole was administered at direction of the treating intensivist. Participants were 
categorised into three groups according to their BMI as follows: normal weight (BMI = 
18.5-29.9 kg/m2); obese (BMI = 30-39.9 kg/m2); and morbidly obese (BMI > 40 kg/m2). 
During one dosing interval, blood samples (≈3 ml) were taken from each participant to 
determine plasma fluconazole concentrations at the following times, pre-dose, at 30 min, 
60 min, 2, 3, 4, 5, 6, 8, 12 and 24 h after dose administration (10 samples for 12 hourly 
dosing, or 11 samples for 24 hourly dosing). Other clinical and demographic data were 
collected on the day of plasma sampling, including: age, sex, total body weight (TBW), 
ideal body weight (IBW), lean body weight (LBW) and BMI 43. Clinical data also were 
recorded including Sequential Organ Failure Assessment (SOFA) 140 and Acute 
Physiology and Chronic Health Evaluation (APACHE) II scores 141, as well as serum 
albumin and creatinine concentrations (Scr) and CLCR estimated by Cockcroft-Gault 
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equation 115 (separately using TBW, LBW and IBW). Urine samples were also collected 
over the dosing interval to determined measured CLCR.  
6.4.4 Sample handling, storage and assay 
Blood samples were placed in an ice bath immediately and centrifuged at 3000 rpm for 10 
min. Plasma samples were stored at -80°C until bio-analysis. Fluconazole was measured 
in plasma by a UHPLC-MS/MS method with a reverse-phase F5 column on a Shimadzu 
Nexera2-8030+ system. Unknown samples were assayed in batches alongside calibrators 
and quality controls and results were subject to batch acceptance criteria. Plasma (100 µL) 
was spiked with internal standard (voriconazole) and acetonitrile added to precipitate 
proteins. The supernatant was isolated and 1 µL injected onto the UHPLC. The stationary 
phase was a Phenomenex Kinetex F5 column, 50 x 2.1 mm, 1.7 μm heated to 30°C.  The 
mobile phase was a 75:25 blend of phase A (0.1% formic acid in 10 mM ammonium 
formate) and phase B (0.1% formic acid in acetonitrile) delivered isocratically at a flow rate 
of 0.4 mL/min producing a typical backpressure of 5500 psi. Fluconazole (retention time of 
0.67 min) was well separated from voriconazole (retention time of 3.93 min) in a run time 
of 5 minutes. Column eluent was directed to the mass spectrometer from 0.3 to 4.5 
minutes. Ionisation was by positive mode electrospray, with fluconazole and voriconazole 
being monitored at 306.7238.2 and 350.0281.1, respectively. The assay method was 
validated for linearity, LLOQ, and precision & accuracy using the FDA and EMEA criteria 
for bioanalysis 129. The method was linear from 0.1 to 20 mg/L.  The precision was within 
3.1% and accuracy was within 3.6% at the three levels tested.  The stability of fluconazole 
in plasma and water stored at -80°C was validated for 19 months. 
6.4.5 Population pharmacokinetic modelling 
The plasma fluconazole concentrations were fitted to one- and two-compartment models 
using non-parametric adaptive grid (NPAG) algorithm within the Pmetrics package for R 
(Los Angeles, CA, USA) 130,131.  
Demographic and clinical characteristics that were considered biologically plausible for 
affecting fluconazole PK were tested for inclusion as covariates. Data including age, sex, 
TBW, IBW, LBW, BMI, Scr, measured CLCR, CLCR estimated by Cockcroft-Gault equation 
(separately using TBW, LBW and IBW), albumin, SOFA, APACHE II were tested. Each of 
these covariates was plotted against the PK parameter estimates to assess for correlation. 
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Covariates were retained in the model if they significantly improved the log-likelihood 
(p<0.05) and/or improved the goodness-of-fit plots.  
6.4.6 Model diagnostics  
Visual inspection of the observed-predicted (population and individual) concentration 
scatter plot was undertaken with the coefficient of determination of linear regression of 
observed-predicted values and the log-likelihood values from each run used to evaluate 
the goodness-of-fit. Predictive performance evaluation was based on the mean of both 
prediction error (bias) and bias-adjusted squared prediction error (imprecision) of the 
population and individual prediction model in central compartment. A visual predictive 
check using n = 1000 simulations was used to evaluate the suitability of the final covariate 
model. Additionally, the AUC was calculated using the Bayesian estimates of the final 
model.  
6.4.7 Probability of target attainment (PTA)  
Monte Carlo simulations (n = 1000) were performed using Pmetrics software to determine 
the PTA for PK/PD targets 25 and 100 the free area under concentration-time to the 
minimum inhibitory concentration ratio (fAUC/MIC) for various measured CLCR values and 
patient BMI 150-152. A free fraction of 12% was used for all simulations. 
Fixed fluconazole loading doses of 200 mg, 400 mg or 800 mg IV 12 or 24 hourly (infusion 
rate 200 mg/60 mins), were simulated from 0 – 24 h at three different levels of renal 
function (measured CLCR = 30, 50 and 150 mL/min) and three BMI groups of 20, 30 and 
40 kg. The PTA for achieving 25 and 100 fAUC/MIC were calculated.   
Weight-based fluconazole loading doses of 3 mg/kg, 6 mg/kg, 9 mg/kg, 12 mg/kg, and 15 
mg/kg from 0 – 24 h for BMI 30 kg/m2 with measured CLCR of 50 mL/min were simulated. 
We also simulated fluconazole maintenance doses of 3 mg/kg/day, 6 mg/kg/day, 9 
mg/kg/day, 12 mg/kg/day, and 15 mg/kg/day from 96 – 120 h for BMI 30 kg/m2 (after a 
loading dose of 12mg/kg on day 1) with three measured CLCR of 30, 50 and 150 mL/min.      
6.4.8 Fractional target attainment calculation  
The fAUC/MIC data for C. albicans and C. tropicalis that are commonly targeted in the ICU 
was used according to MIC distributions from the European Committee for Antimicrobial 
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Susceptibility and Testing (EUCAST) database 151 to determine the fractional target 
attainment (FTA). The FTA describes the pharmacodynamic exposure (PTA) of 
fluconazole against an MIC distribution. This FTA threshold was attained when the value 
was ≥ 90%. Susceptible MIC distributions of both pathogens (MIC ≤ 2 mg/L) were used to 
determine the FTA for directed therapy. Additionally, we determined the FTA for the entire 
MIC distribution (including susceptible and resistant isolate values) to describe the 
adequacy of dosing that would be encountered during empirical therapy.  
6.4.9 Statistical analysis 
Continuous variables are presented as mean (standard deviation) or median (interquartile 
range) as appropriate. Categorical variables are expressed as absolute numbers and 
relative frequencies. The Kolmogorov–Smirnov and Shapiro-Wilk tests were used to test 
for normality.  A one-way analysis of variance (ANOVA) was used to test for differences in 
demographic and clinical data between the BMI categories. Linear regression was used to 
describe correlations between patient weight metrics in the three BMI categories with 
fluconazole volume of distribution in the central compartment (Vc) and clearance. All 
statistical analyses were performed using the statistical software package IBM-SPSS 
statistics 22.0 (IBM, New York, USA). A P value <0.05 was considered statistically 
significant.  
6.5 Results 
6.5.1 Demographic and clinical data 
Twenty-one critically ill patients (11 males) were enrolled in the study, eleven non-obese, 
six obese and four morbidly-obese patients. In total 215 blood samples were obtained from 
the participants. The demographics and clinical characteristics of the respective BMI 
categorisations are shown in Table 6-1. Only patients’ TBW, LBW and BMI were 
significantly different between the three BMI categorisations (P < 0.05).   
6.5.2 Pharmacokinetic model building 
Fluconazole PK was best described using a two-compartment linear model. The model 
goodness of fit was improved by inclusion of the covariates measured CLCR (normalised to 
the population mean 105 mL/min) for fluconazole clearance and by BMI (normalised to 30 
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kg/m2) for fluconazole Vc. Furthermore, addition of both resulted in a statistically significant 
improvement in the log-likelihood from the previous model (P <0.05).  
Measured CLCR, Cockcroft-Gault (based on total body weight) and Modified Diet in Renal 
Disease equations were each tested as potential covariates for fluconazole clearance. 
None of these CLCR measures resulted in a statistically significant decrease in the log-
likelihood. However, of these, the lowest log-likelihood was associated with inclusion of 
measured CLCR in the model. The addition of this covariate improved the agreement 
between the observed and population-predicted concentrations as well as distribution of 
observed data within the visual predictive check and so was retained in the final model.  
Addition of BMI as a descriptor of Vc to the final covariate model was performed even 
though there was no positive correlation evident between Vc and BMI. This decision was 
based on biological plausibility and because the addition resulted in a clear improvement 
of the observed and population-predicted concentration goodness of fit plot as well as the 
visual predictive check plot. 
The final covariate model was as follows:   
TVCL= CL*CLcr/105 
TVVC=Vc*BMI/30 
Where TVCL is the typical value of fluconazole clearance, CL is the population parameter 
estimate of fluconazole clearance, CLCR is the measured creatinine clearance, TVVc is the 
typical value of fluconazole distribution in the central compartment, Vc is the population 
parameter estimate of fluconazole volume of distribution of the central compartment, BMI 
is the body mass index.     
The mean ± SD population PK parameter estimates from the final covariate model are 
shown in Table 8-2. The diagnostic plots confirmed the appropriateness of the model as 
shown in Figure 6-1 and 6-2. The final covariate model was then for Monte Carlo dosing 
simulations.  
6.5.3 Dosing simulations 
Monte Carlo simulations and PTA for achieving 25 and 100 fAUC/MIC for fixed 200 mg, 
400 mg and 800 mg daily doses are presented in Table 6-3. For fAUC/MIC of 25, the 
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results showed that at all morbidly obese patients failed to achieve the PK/PD target for 
MIC of 2 mg/L at lower fluconazole doses (200 mg daily). For higher doses (800mg daily), 
there was failure to achieve fAUC/MIC of 25 for an MIC of 8 mg/L. For the fAUC/MIC of 
100, all simulated morbidly obese patients failed to achieve the PK/PD target for MIC of 
0.5 mg/L at a fixed 200 mg daily and for MIC of 2 mg/L at higher fixed 800 mg daily dose.
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Table 6-1. Demographic and clinical data (one column for each BMI category). 
 
All Patients  
(n = 21) 
Normal weight patients 
(n = 11) 
Obese patients 
(n = 6) 
Morbidly obese 
patients (n = 4) 
 
Variable Mean (SD) Mean (SD) Mean (SD) Mean (SD) P Value 
      
Age (Year) 54 (15) 55 (18) 53 (15) 54 (7) 0.97 
Weight (kg) 90 (24)  74 (10) 98.1 (17) 122 (23) <0.001 
Ideal body weight (kg) 64 (10) 67 (7) 66 (12) 55 (11) 0.09 
Lean body weight (kg)  56 (10) 56 (6) 62.5 (11) 47 (10) 0.03  
Height (cm) 171 (11) 173 (8) 172 (13) 163 (13) 0.29 
Sex (male)* 11 (52) 7 (64) 3 (50) 1(25) - 
BMI (kg/m2) 31 (9) 25 (3) 33 (3) 46(6) <0.001  
Scr (µmol/L) 74 (35) 62 (21) 83 (40) 94 (52) 0.22 
Measured CLCR (mL/min) 106 (54) 108 (45) 89 (27) 125 (103) 0.60 
CG-TBW (mL/min) 142 (85) 127 (57) 135 (66) 192 (159) 0.43 
CG-IBW (mL/min) 102 (52) 113 (47) 89 (40) 90 (84) 0.60 
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CG-LBW (mL/min) 89 (45) 95 (41) 84 (38) 78 (72) 0.81 
SOFA score 5 (2) 5 (2) 6 (3) 3 (1) 0.29 
APACHE II score 20 (5) 19 (2) 21 (7) 22 (8) 0.48 
Legend - APACHE II = Acute Physiology and Chronic Health Evaluation; BMI = body mass index; ClCR = measured creatinine clearance; 
CG-TBW = estimated CLCR using Cockcroft-Gault equation based on total body weight; CG-IBW = estimated CLCR using Cockcroft-Gault 
equation based on ideal body weight; CG-LBW = estimated CLCR using Cockcroft-Gault equation based on lean body weight; Scr = 
serum creatinine concentration; SOFA = Sequential Organ failure Assessment.  
*Data is significantly different between BMI groups.  
**Data of male’s gender is presented as number (%).   
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Table 6-2. Parameter estimates for fluconazole from the final covariate two-compartment 
population pharmacokinetic model.  
 Mean (SD) Coefficient of variation (%) Median 
CL (L/h) 0.95 (0.48) 50.47 0.86 
Vc (L) 15.10 (11.78) 78.07 8.55 
KCP (h-1) 5.41 (2.28) 42.21 5.42 
KPC (h-1) 2.92 (4.95) 170.00 1.04 
CL = population clearance of fluconazole; Vc = population volume of distribution of central 
compartment; kcp = rate constant for fluconazole distribution from the central to peripheral 
compartment; kpc = rate constant for fluconazole distribution from the peripheral to central 
compartment. 
 
Figure 6-1. Diagnostic plots for the final population pharmacokinetic covariate model.  
(a) Observed fluconazole concentrations versus population predicted fluconazole 
concentration (R2 = 0.627). (b) Observed fluconazole concentrations versus individual 
predicted fluconazole concentration (R2 = 0.967). 
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Figure 6-2. Visual predictive check of fluconazole plasma data. 
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Table 6-3. Fluconazole probability of target attainment at different BMIs, CLCR, and loading dosage regimens (fAUC/MIC value of > 25 
and > 100). 
   fAUC/MIC > 25 fAUC/MIC >100 
   MIC (mg/L) *  
BMI (kg/m2) Dose 
CLCR 
(mL/min) 
0.12 0.25 0.5 1 2 4 8 16 0.12 0.25 0.5 1 2 4 8 16 
20 
20
0 
m
g 
 
30 + + + + + - - - + + + - - - - - 
50 + + + + + - - - + + + - - - - - 
150 + + + + + - - - + + + - - - - - 
30 30 + + + + + - - - + + + - - - - - 
50 + + + + + - - - + + + - - - - - 
150 + + + + + - - - + + + - - - - - 
40 30 + + + + - - - - + + - - - - - - 
50 + + + + - - - - + + - - - - - - 
150 + + + + - - - - + + - - - - - - 
20 
40
0 
m
g 
 
30 + + + + + + - - + + + + - - - - 
50 + + + + + + - - + + + + - - - - 
150 + + + + + + - - + + + + - - - - 
30 30 + + + + + + - - + + + + - - - - 
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50 + + + + + + - - + + + + - - - - 
150 + + + + + + - - + + + + - - - - 
40 30 + + + + + - - - + + + - - - - - 
50 + + + + + - - - + + + - - - - - 
150 + + + + + - - - + + + - - - - - 
20 
80
0 
m
g 
 
30 + + + + + + + - + + + + + - - - 
50 + + + + + + + - + + + + + - - - 
150 + + + + + + + - + + + + + - - - 
30 30 + + + + + + + - + + + + + - - - 
50 + + + + + + + - + + + + + - - - 
150 + + + + + + + - + + + + + - - - 
40 30 + + + + + + - - + + + + - - - - 
50 + + + + + + - - + + + + - - - - 
150 + + + + + + - - + + + + - - - - 
* Fluconazole target MIC was defined according to EUCAST susceptibility breakpoints (2 mg/L). 
 (+) at least 90% of fluconazole probability of target attainment is achieved; (-) fluconazole probability of target attainment failed to 
achieve 90%; BMI= body mass index; CLCR = creatinine clearance; fAUC/MIC = the area under the concentration-time curve at steady 
state; MIC = minimum inhibitory concentration.  
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6.5.4 Fractional target attainment   
The FTA for the different scenarios are shown in Tables 6-4 and 6-5 respectively. For 
fAUC/MIC of 25, all fluconazole dosing regimens successfully achieved the 90% target for 
both empirical and directed therapies. For fAUC/MIC of 100, the lower fluconazole dose 
(i.e. 200 mg daily) achieved 90% coverage of C. albicans for directed therapy in only 
patients with normal weight group at the lower measured CLCR 30 and 50 mL/min. The 
higher fluconazole regimen (800 mg daily) was required to achieve 90% FTA of both C. 
albicans and C. tropicalis for directed and empirical therapies in all BMI groups at different 
levels of measured CLCR.   
6.5.5 Fractional target attainment at different fluconazole weight-based loading and 
maintenance doses  
The FTA for various weight-based dosing regimens from 0 – 24 h and separately from 96 
– 120 h are shown in Figure 6-3 and 6-4. These data show that a loading does of at least 
12 mg/mg was required for the fAUC/MIC target of 100. Furthermore, a maintenance dose 
of at least 6 mg/kg/day (TBW) required to achieve fAUC/MIC of 100 (assessed between 96 
and 120 h of therapy).  
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Table 6-4. Fractional target attainment of fluconazole loading dose (0-24 hrs) at different BMIs and CLCR (fAUC/MIC value of 25). 
   fAUC/MIC > 25 
BMI (kg/m2) Loading 
dose  
CLCR 
(mL/min) 
Candida albicans Candida tropicalis 
   Directed 
Therapy  
Empirical 
Therapy 
Directed 
Therapy  
Empirical 
Therapy 
20 
20
0 
m
g 
 
30 99.1%  95.0% 98.7% 95.0% 
50 99.1% 95.0% 98. 7% 95.0% 
150 98.1% 94.0% 98.4% 94.3% 
30 30 99.0% 94.2% 98.0% 94.2% 
50 99.2% 94.1% 98.0% 94.1% 
150 99.5% 94.3% 98.4% 94.3% 
40 30 98.5% 93.4% 96.1% 93.4% 
50 98.5% 93.3% 96.0% 93.3% 
150 98.0% 92.5% 93.0% 92.5% 
20 
40
0 
m
g 
 
30 99.9% 96.2% 99.5% 96.2% 
50 99.9% 96.0% 99.5% 96.0% 
150 99.9% 95. 5% 99.5% 95.5% 
30 30 99.7% 95.5% 99.3% 95.5% 
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50 99.7% 95.4% 99.2% 95.4% 
150 99.9% 95.5% 99.5% 95.5% 
40 30 99.5% 95.1% 98.7% 95.0% 
50 99. 5% 95.0% 98.7% 95.0% 
150 99.5% 94.7% 98.6% 94.7% 
20 
80
0 
m
g 
 
30 99. 5% 95. 0% 99.9% 97.0% 
50 99. 5% 95.0% 99.9% 96.9% 
150 99.5% 94.3% 99.9% 96.5% 
30 30 99.9% 96.5% 99.7% 96. 5% 
50 99.9% 96.5% 99.7% 96.5% 
150 99.9% 96.5% 99.9% 96.5% 
40 30 99.9% 96.2% 99.5% 96.2% 
50 99.9% 95.2% 99.5% 96.2% 
150 99.9% 96.0% 99.5% 95.9% 
*Dose, BMI and CLCR values that did not achieve the target of fractional target attainment against at least 90% of isolates are included by 
bold %.  
BMI = body mass index; CLCR = creatinine clearance; fAUC/MIC = the area under the concentration-time curve at 0-24 h; MIC = minimum 
inhibitory concentration. 
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Table 6-5. Fractional target attainment of fluconazole LD (0-24 hrs) at different BMIs and CLCR (fAUC/MIC value of 100). 
   fAUC/MIC > 100 
BMI (kg/m2) Loading 
dose  
CLCR 
(mL/min) 
Candida albicans Candida tropicalis 
   Directed 
Therapy  
Empirical 
Therapy 
Directed Therapy  Empirical 
Therapy 
20 
20
0 
m
g 
 
30 94.4% 89.3% 81.9% 89.3% 
50 93.6% 88.6% 79.3% 88.6% 
150 89.5% 84.7% 65.7% 84.7% 
30 30 89.9% 85.1% 68.8% 85.1% 
50 89.3% 84.5% 66.8% 84.5% 
150 89.5% 84.7% 65.7% 84.7% 
40 30 86.1% 81.5% 59.6% 81.5% 
50 85.6% 81.0% 58.2% 81.0% 
150 80.7% 76.3% 47.3% 76.3% 
20 
40
0 
m
g 
 
30 98.4% 93.2% 95.7% 93.2% 
50 98.2% 93.0% 94.7% 93.0% 
150 96.6% 91.4% 87.7% 91.4% 
30 30 96.7% 91.5% 88.9% 91.5% 
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50 96.4% 91.2% 87.9% 91.2% 
150 96.6% 91.4% 87.7% 91.4% 
40 30 94.8% 89.7% 83.3% 89.7% 
50 94.5% 89.4% 82.4% 89.4% 
150 92.4% 87.5% 75.2% 87.5% 
20 
80
0 
m
g 
 
30 99.5% 95.0% 98.7% 95.0% 
50 99.5% 94.9% 98.7% 95.0% 
150 99.5% 94.3% 98.4% 94.3% 
30 30 99.2% 94.2% 97.8% 94.2% 
50 99.2% 94.1% 97.7% 94.1% 
150 99.5% 94.3% 98.4% 94.3% 
40 30 98.5% 93.4% 96.1% 93.4% 
50 98.5% 93.3% 95.8% 93.3% 
150 97.7% 92.5% 92.7% 92.5% 
*Dose, BMI and CLCR values that did not achieve the target of fractional target attainment against at least 90% of isolates are included by 
bold %.   
BMI = body mass index; CLCR = creatinine clearance; fAUC/MIC = the area under the concentration-time curve at 0-24 h; LD = loading 
dose; MIC = minimum inhibitory concentration.
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Figure 6-3. Probability of target attainment (fAUC/MIC of 100) from 0 – 24 hrs of different 
fluconazole loading doses (mg/kg) for a BMI 30 kg/m2 with CLCR of 50 mL/min.  
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Figure 6-4. Probability of target attainment (fAUC/MIC of 100) from 96 – 120 h for a patient with BMI 30 kg/m2 at three simulated CLCR of 
30, 50 and 150 mL/min administered different maintenance doses of fluconazole. 
 (a) 3 mg/kg/day, (b) 6 mg/kg/day, (c) 9 mg/kg/day, (d) 12 mg/kg/day.
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6.6 Discussion  
6.6.1 Key findings 
This is the first population PK study of fluconazole in critically ill non-obese, obese and 
morbidly obese patients. Fluconazole PK/PD targets of fAUC/MIC > 25 (for fungistatic 
effect; 150) and of > 100 (for a high probability of cure for Candida spp with MIC up to 2 
mg/L150) were both tested due to the uncertainty of which PK/PD ratios should be targeted 
to ensure successful treatment.  We found that a fluconazole dosing regimen of 200 
mg/day was sufficient to achieve the PK/PD target of fAUC/MIC > 25. However, a higher 
fluconazole dosing regimen, 400 mg or 800 mg/day, is required to achieve the higher 
target of fAUC/MIC > 100.  We believe a more accurate approach to dosing, may be 
through the use of a weight-based approach which includes a loading dose of 12 mg/kg 
and a mg/kg maintenance dose guided by measured CLCR. 
6.6.2 Relationship with previous papers 
Despite the common use of fluconazole in the ICU, there is a significant shortage of robust 
PK studies of this drug on obese critically ill patients. Lopez and Phillips in a recent case 
report of a morbidly obese patient (BMI = 272 kg, 84.0 kg/m2) on RRT, reported the use of 
a 12 mg/kg fluconazole loading dose (based on LBW) followed by a maintenance dose of 
6 mg/kg 75,153,154. The resulting fAUC was 163.8 mg.h/L (assuming 11% protein binding) 
which would be sufficient to achieve the PK/PD target of fAUC/MIC > 25, but not quite the 
higher PK/PD target of fAUC/MIC > 100. In another case report of a morbidly obese 
patient (BMI = 48.3 kg/m2; measured CLCR = 125 mL/min), Cohen et al reported the use of 
a 1200 mg daily dose, administered as a 6-h infusion, with the resulting measured fAUC of 
494.4 mg.h/L (assuming 11% protein binding). This dose was sufficient to achieve both the 
lower and higher PK/PD targets 77. Both case reports in critically ill patients support use of 
higher than standard doses in obese patients.  
In a study of critically ill non-obese patients with normal renal function, a standard 
fluconazole dose of 400 mg daily (< 6mg/kg) resulted in suboptimal exposures leading to 
failure in achieving PK/PD targets 9. The authors suggested that higher fluconazole doses 
are required in some patients with higher body weights. Therefore, individualized weight-
based fluconazole dosing is recommended to ensure PK/PD target achievement. The 
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results of the aforementioned study supports the current study, which demonstrated that 
fluconazole at lower dosing failed to achieve the desired PK/PD in various scenarios. In a 
population PK study of fluconazole in critically ill patients receiving continuous veno-
venous hemofiltration (CVVHDF), fluconazole clearance was higher than previously 
observed 155. Thus, this study recommended that higher fluconazole dosing is required in 
patients undergoing CVVHDF. The authors recommended a fluconazole loading dose of ≥ 
12 mg/kg followed by 6 mg/kg maintenance dose. This recommendation matches the 
findings of the current study which showed that patients with measured CLCR ≥ 150 
mL/min (i.e. higher drug clearances) require a higher loading (12 mg/kg) and maintenance 
dose (at least 6 mg/kg).   
6.6.3 Implications of study finding 
Fluconazole remains an important antifungal drug to prevent and treat Candida spp. Given 
the increased prevalence and resistance of non-albicans Candida infections, critically ill 
patients, including obese and morbidly obese, should be given antifungal therapy that 
optimises clinical outcomes as well as to minimise resistance. EUCAST recommends that 
a fluconazole PK/PD target of fAUC/MIC > 100 be used for high probability of cure. 
Accordingly, we found that standard fluconazole dose (200 mg daily) was insufficient for 
directed and empirical therapy for C. albicans and C. tropicalis in non-obese, obese and 
morbidly obese critically ill. Thus, if a fixed dosing approach is to be used, higher 
fluconazole dose (400 mg daily or higher) should be considered for directed therapy 
However, empirical therapy for C. albicans as well as directed and empirical therapies for 
C. tropicalis might require even higher fluconazole doses (i.e. > 800 mg daily).  
When testing a weight-based dosing approach, we found that a fluconazole loading dose 
of 12 mg/kg/day followed by maintenance dose of 6 mg/kg/day was required to provide 
sufficient attainment of PK/PD targets regardless of patient weight and BMI. This finding 
results from our observation that fluconazole Vc was related to BMI of which weight is an 
important determinant. We also found that fluconazole clearance is correlated with 
measured CLCR. Consequently, fluconazole maintenance dose should be calculated 
according to renal function assessed by measured CLCR. 
6.6.4 Study limitations  
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Although this study is the first population PK of fluconazole in critically ill non-obese, obese 
and morbidly obese patients, it has some limitations we would like to declare. Firstly, the 
sample size is not sufficient for quantifying the effect of fluconazole exposure on patients’ 
outcome. Furthermore, a larger sample size may have enabled more covariate 
relationships to be demonstrated, although we believe that BMI and measured CLCR are 
likely to be the two most significant determinants of dosing. Secondly, we did not measure 
fluconazole plasma concentrations at the site of infection which may provide better 
mechanistic data regarding the effectiveness of dosing. Thirdly, blood samples were 
collected only from one dosing interval and levels may change within patients over time. 
6.7 Conclusion 
In this study, which included critically ill obese and morbidly obese patients, we 
demonstrated that fluconazole clearance was correlated with measured CLCR, while Vc 
was best correlated with BMI. The results of this study suggest that a higher fixed 
fluconazole dose (i.e. ≥ 400 mg daily) is required in these patients when they are infected 
by less susceptible Candida spp. (MIC > 2 mg/L).  Our results show that a loading dose of 
12 mg/kg followed by a maintenance dose 6 or 12 mg/kg/day is required to achieve either 
the low or high PK/PD targets. Finally, loading doses should be weight-based whereas 
maintenance doses should be prescribed according to renal function. Further clinical 
studies of fluconazole are warranted to determine the effect of optimized dosing on clinical 
outcome.      
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7.1 General discussion on the findings of this Thesis and provides suggestions for 
further research 
7.1.1 Summary of findings 
Optimised antimicrobial dosing in critically ill patients is highly challenging, but is important 
for improving patient outcomes. Antimicrobial PK can be affected by common 
pathophysiological changes that occur in critically ill patients including increased cardiac 
output, fluid shifts, and renal and/or hepatic dysfunction. In obese critically ill patients, 
additional pathophysiological variations can occur, such as impaired perfusion of 
peripheral tissues, increased cardiac output, increased body fat tissues, and lean mass. 
Together, these effects increase the likelihood of significant alterations in antimicrobial PK, 
including changes to volume of distribution, protein binding, and clearances. Since PK 
alterations can occur in critically ill patients who are obese, specific altered dosing of 
antimicrobials is required for these patients to ensure therapeutic plasma concentrations 
are achieved.   
The key aims of this Thesis were to examine the PK of the antimicrobials, meropenem, 
piperacillin, and fluconazole, in critically ill non-obese, obese, and morbidly obese patients.  
The first major study of the Thesis was a retrospective investigation of a large dataset 
(n=1400 patients) of piperacillin and meropenem TDM data to determine the effect of 
obesity on unbound trough concentrations and achievement of PK/PD targets of these 
antimicrobials (100% f T>MIC). This study found that patients, who have CLCR between 51 
and 100 mL/min, have higher trough concentrations in the piperacillin group when the drug 
was administered by a prolonged infusion. This relationship was not seen in the 
meropenem group. For a higher PK/PD target of 100% f T>4xMIC, only the piperacillin group 
was associated with significantly lower PK/PD target attainment in the obese patients. This 
study highlighted that when using hydrophilic and renally excreted antimicrobials including 
piperacillin and meropenem, lower plasma concentrations are likely to occur at higher 
CLCR, potentially leading to therapeutic failure.  
 
The second study conducted as part of this Thesis was a study of the effect of obesity on 
meropenem PK in critically ill patients. Higher CLCR (≥ 150 mL/min) was associated with a 
lower achievement of PK/PD targets for all patients. The standard dosing regimen (1 g 
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eight-hourly as a 30-min infusion) was found to achieve PK/PD targets for patients with low 
and normal kidney function. In almost all dosing scenarios, meropenem achieved PK/PD 
targets successfully with the exception of lower doses in the presence of high CLCR (>150 
mL/min). For therapy directed at a susceptible pathogen with a MIC < 2 mg/L, dose 
adjustment was found to be rarely necessary. However, when meropenem was used as 
part of empiric therapy before the susceptibilities of the pathogen is known, depending on 
local susceptibility patterns, in the case of possible A. baumannii and P. aeruginosa, 
higher doses and/or use of prolonged infusion should be considered until the pathogen 
and susceptibility have been characterised.  
The third study conducted as part of this Thesis found that both more frequent intermittent 
piperacillin doses as well as administration by extended or continuous infusion greatly 
improved PTA (up to at least 8 mg/L) in non-obese, obese and morbidly-obese critically ill 
patients. Even though a measured CLCR was found to be the major determinant of drug 
exposure, extended and continuous infusions were found to normalise any effects of 
altered weight and renal function on the achievement of therapeutic concentrations.  
The final study conducted as part of this Thesis examined the ability of different 
fluconazole doses to achieve two PK/PD targets fAUC/MIC > 25 and > 100, in non-obese, 
obese and morbidly-obese critically ill patients. Both targets were considered due to the 
uncertainty of the PK/PD targets required for successful treatment. A fluconazole dosing 
regimen of 200 mg/day was found to be sufficient to achieve the PK/PD target of 
fAUC/MIC > 25. However, a higher fluconazole dosing regimen, 400 mg or 800 mg/day, is 
required to achieve the PK/PD target of fAUC/MIC > 100. A weight-based approach to 
dosing is most likely to be successful for achieving therapeutic concentrations, including a 
loading dose of 12 mg/kg and a maintenance dose guided by renal function. 
7.1.2 Suggested future research  
There are numerous factors to be considered and several strategies that can be 
contemplated, in order to ensure obese patients receive appropriate antimicrobial dosing 
regimens.  Further studies are suggested to address the following concerns. 
1. There are difficulties and a lack of an appropriate strategy to measure critically ill 
patients’ weight, particularly if they are obese. Consequently, patient’s self-reported 
weight, or weight predictions by clinicians or nursing staff, are used instead. This 
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increases the risk of inappropriate weight-based dosing and can lead to sub or supra-
therapeutic antimicrobial exposure. Therefore, a study to enable more feasible 
measurement of actual patient weight would increase the accuracy of dosing.    
2. Therapeutic drug monitoring is an important strategy to guide antimicrobial dosing by 
measuring drug plasma concentrations to improve the likelihood of the desired 
therapeutic drug level. Therefore, a well-designed study evaluating the clinical 
outcomes associated with antimicrobial dose adjustment using TDM approach is 
strongly encouraged. This will help to confirm similarities or differences in dosing 
regimens required between obese and non-obese critically ill patients.  
3. There have been previous studies describing the dosing requirements for piperacillin 
and meropenem, in critically ill patients receiving RRT. However, there is yet to be such 
a study specifically in obese and morbidly obese patients. A PK study to determine 
dosing requirements in obese and morbidly obese critically ill patients receiving RRT 
would be of interest to clinicians. 
4. All of the studies in this Thesis measured drug concentrations in plasma. Given that 
plasma PK is used as a surrogate of PK at the site of infection (e.g. epithelial lining fluid 
in pneumonia), further PK studies are suggested to describe the antimicrobial 
concentrations PK in the interstitial fluid of tissues using the in vivo sampling technique, 
microdialysis. These suggested studies would be of value to understand the 
antimicrobial concentrations at the site of infection.   
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